var title_f21_23_21872="Portable hyperbaric chamber";
var content_f21_23_21872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Portable hyperbaric chamber",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 260px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0+3KSMQrDPoRU21EPYE9SKoRn/WPt5PTBqeCJiD5h256ZPNaexkb8yHpKrZ/djcO5706Pfgbguc9KqSm3gkWKSbLseBnvT1yFRJXCc9QaPYyGmiWV1hjd5PlCjNQLdBsGPqRxSoYZUkCP5zn5cU9YQrplFBA7UexkO46N5HuVDfcxzxVrfHuCEgE02eVYUHykk9qr3FsZlGCQD6UexkBcDbHwoGO9HmFn4GF9aiSExgDJOFA5oUssbE5GDxR7KQXROVLNtJH0xTlhx90c1VErl8knpxUnmbhktg0nSkFyyrGPIbGe9PWfyhnIINVonVgUYjJ/OnJ8oxs74zS9lICVpGkYEcE9KcTnac8DrR95OBgiklOYisYw1L2UhEhAJBCgg96YSfMwuSR+VOhdliXeORQJQGBAALU/ZyC4iKWyR+NLECh+YgelSJGvmN2OM5pTGrqAGz70nTkCkiPnfknH1qKSORzkyEDParKxkDZ1HY0+NAuQeTR7OQ7ohiUxIwJz71MDsw27tTHlXzTE6nJHapPLAxt6Y6U/ZyHcaxSQ8Y3etNk37du9cepqRoAw9DTWskYcsRR7KQXKoaSFQjeZITzu4FW1jbgbsAjPPNSfZh9mIncKu3lvQVLbxxJEojfegHDetHspCuRxxM2QXXjpxSGI9nz9KkMbu5CHFSR2/lpk5LE9aPZsLlTy2Y7cGlW3Xr6da0tm1dxIzUEhwwCkc0ezYrlWOJvlAkUc+lOlIjxv5OO1DNISp4ADU1xKDjqM/pR7OQXuN80PGpQ/N64pI13cu2T2qQqACewpVKAYPaj2cgIXjBA9aUQKSOnqM1M43D93waaeRtPUUeykIqbHMxPAU9cCiVfK+4QoPc1NNhUwQ2R0xUMkZkVCAODzu60/ZyC5G0pRCWckDrimJMJU3RnIPQmrghVt4jQDjnNQhEjkKqApPaj2chcxCpNrHtZ0DOcA4pwjCYaSZc9xTnQEZcFj0z6U0QNv2yKGQ0vZyHzE6svzY2nPtUbbXO0ADHpTWDIXVFPPSlkhaSBQXwRzxQqcg5kTj5QAoyc8U9ivBAwR1NVY1ePADEg9c1HNKznLLhugPaq9kwvcfPOQ25Tj3Iqk32ia6UyS7VHQL3q8oMsQV5BkdcVGypFKAWzn17UeyYXIGgjWYtht3qTUaqWJAYn3FWpsOdv8PrSpGsK9Fwe1P2UguVY7WXvIGX361FJCIX3LyTxirpkQEMowT2om+7kMNx7U1Rb6hcwZNoBVB82M8Uz7STHiThz+lXo0jV2L8Fh1PakdVYZ2gkHsM1jzyKsirFAGnUsod+zEc1bazLksx5pzyFHRmj2r0GBUtxdiOEssbMx/h6Uc8hlYW3krm2j2e460qxSnDDdnPJNPaVmjU7WGRnr0pySRkKzvJn0HSjnkAo85sknO3oKsINifO4FRPJGQfL3c+pqGONUBYvk+p7Uc8u4FtW38g9KchzIo7YPFUg3zfK2R7VIk+FLY5AwBmlzPuLlLwUYUnmmtGjHIHPpVZZSIlbPJ6ClM8isGx2xihyfcdrCNZ/vdx4LDg1IpmiXBGSOAPeorT7TlvOkDgnK8Y2094pjIQcknow7UrvuA8zSRlQUYsetTqQVY7ieO1V4hJESZG3Mvc96lEp37QBjHIFPmfcBtpLPJGxkQqAcDd3HrUw2nap2ls9KrJcPMGAU7YzjNRx4M3mAblHbNK77jNLzCcgDIIxnNECCIAbiQexNQoGQAIoAPrU38W0j8aV33FuTbz0ycCnK6nO7rUK/KwBOQakwj9F5p3YWFO0PuXeQo5CnrUVnN9qjZ490QViNrdasKBG/DYJ7ipFZVJJUnPU7eKLvuIezBUUrgkj0pudyZJpTInYD2pFUdz1/SnzPuBHKYJYnRyzqwwQKW3jEMCxRDCr90elSxIvzNtH4cYp+xVUFeCe+etJt9x7iLlkIU7W9u9JOBJOhE0ihRyoPBqK4cxRswwW7c4piu7YJ2j8aWvcLInmd+Ap6+tRry+BncO9MfLqMHP07VHJ5zRsqOFOOuKNe4ySYMx4OAPSkUt5ZO48VGGcIgZskdfenMCUbBwCfyou+4hMkcl8Ajv0oVlHzb9x9qTAZioIO0fnQ4jwCQFNF33CxKR8wwx5pjMSfm6jofWoDIVcZUlcZ3CpT88fyKS56H0p8z7isOeXI+bcM9cVEZFK8BgBzn1pIlbaVlfc3fjFTKpYYC8D3o5n3ARHBTIU5pjjOGZQT71MG2g8AfrUTMzfMcY7Ucz7h8hCecdAe1BXbw34GopX+UscDbzjNNjn3om8ct05o5n3D5EzStnBXNKki5PzbT6GqsgAm3JuA9CasxxKw3cfzoUpdwsiMCUSn59+exqTy96r5vA9KUybGAK/j6VLJKmUWhyfcLEEqRrIRHxmq80DeZuL5GO/NW5GjLSDvjrVO6nhhRcsxL8ACjmfcLDGUryGBHpmjyd4VnOcVWV3d3zDtRTwS2c1IZizeWD94demKPaeYWHeW0fAGV5IJNRthwpGd+KayxJIN8rswGODwaTzlVTgE01MOUpR72VVcean9496likjSPcGIPtzVVLQTrBI0ssSxngAjBq03loASRjOOO9ADpL9QBt+bdwDjvR54cDecEe1MKR9AuMHNMfb5Ss3PNA0SxNgtiUYB4BpjFmJ2hmGe1VYHgknaMBiQOp4q4k6qgKgqqjBOetAyOVJAu5UIx781RinuHD/utoH9+tBrpDA7hwRjj1FVTqcCI0jQylQBliKAJo5CEUgckdqtxRlickYIqISQShXRvlYbgB6VKJpCpjEQCnox61IXJFhwy7Dn61MSIwNwyaz3dg/lbmjU/xYqSHIyA5kI9aBMuidWYAK2fpUzM2flDZrNe+S1aNJFfzJOm0ZC1aEo7NJu9cUCHmVRkSMqsezdaSUoSUaMkt/EpqPakkv7xGZvUil2uc7vkUdMUxhZwQW5dYlcBvvZPepXWKFQucHPamLkAZH60tvGJcllHB45pATRzxPxvGR71JvBACkGo44ozMSsQGOvFWEEZBCpg9qAGrIyyFNhPHpT1Z1QkjHNLAJAd7nkVK/II7mgBYwrbWB/OmOHdjgcexqvdrN9nk+ysI3A6nnNTWvmvGm4/vMDc3TNAALVim8swAOcVIm8oWRhzTt7DqxA6GieYQxbwPkHXAoBgvmRliZAzEdPShpNmwN93HOPWoy+QXDH5h6U3LhFxz+FAIbcJ5+Q6Ar255pI4NqDadv41LGz5+bj8KcAGyuOaYCxxCMktNkmkkjHGHJqOQbdoA570EjOTwBSAEMbNhs/WnCJFGQ5bnoabvj6AHJp20P35oAGQLnA2g0yQZUADcvvUjhs5JyBTN34CgCP96qFegzjilChgd7FV6cGnLLGykK2AOtRLGVJGd6P3NIAKJnKsQPenligG0k+1NeL5htORT0UjgnA9aaAHnCgAjBqKSRR8y/ex/FxmnSqG7A47imLHG+AfmI9aAKyO11ES+6Jt2OO9TAFhEGwwQ+ozTzCN43Hp0FMVcFXIwM9aAH7D1wacpd+OgHPpTHJ2ttJZhnpUcLXQb95goanUCbeWY96kdQwBzSbQOeg9qikYKgKAk5oQMS4YqWwMcVWB83apAyKsOzNF8y980DaTuIAIFMEMEQ5U5JHeoZmVHEaqSx6npUrXQ3EFeOmfSmIQFJzuNHL1KIlZCceXgipJANmdmMUk08EcTF2QA9OeaopfASbSrsAN249PpTsIrs5QKmVwecE1BdSKkRY5J3Z2gVDcsj3GJUPH8VPhKIT+/R1HRc5NdKoSsTfU0ILiJ4xu+XjJqPcsjYUgoKYsaum5eAfWlGyIAFc571Psmtx37EkiqAxAO/1rNnjZnTYWKD7wqbUr210+2ea6l2Knvya4PUPG13LKy2UaxR9A5HJ963pYGpPYxqYiMNzvLdkjQlgApP8AEcVJ5yMxyQyntkYrxm71DULpx591I3OcA4quLm6j5S7nH/Aq61lUmtZI53j4roe5wPG+VQKhH0q0HyAVOccdc14ELzUOSL64DH0ep4tY1SHAj1C4GP8Ab60PKJdJIFjo9j6ATdwuwY96G+UHpk+grxKLxdr0ZH+mZA/vDNWI/G2tq2TPGx/651H9k1ejQ/rsGewxkKUyuSPUVMZ+GA6+9eOnx/riuCHhyOv7sUh8d62zbvMhB68IKX9k1u6D67A9ettQdw6iNiV7nIqykpJUun/Aa8W/4TzXsNieIA9fkpYviBrp2jfASO+wU/7Jrd0H12B7O7rJKVCEH1xxUkKIvAGB1NePH4ia0VwRBn1Cdali+IuqrgtFAT9Kh5XW8ili6Z7OHQkFTjHWnGSNWXjnsa8ht/iZfLxJaQt+NWF+J0wJMmnoQOBh6X9mVluNYqmesytuc8cEdqQvjACmvKYfiY6ly1jkntv6VKvxQcHnThj/AHqX9m1R/WqZ6htbqMYPaps8AFcAdxXlp+KgyANN4/36lX4pxhiZNPfb6Bs0v7PrD+tQ7np23PzKRj1NMZlCkls+orzyH4o2GPnsbgew5qYfEzSGcB4rhB6YpPAVV0D6zDudoiHZyxPNTbTwcHjpXIQfEHQJAc3Ei56ZSrcXjbQz8p1EJ9RUfU6nVFqtB7M6VyWK8svtnrQGKucBR+NYcXijRZOP7Vtyp9Tg1OuqaRcYKajAWHo9S8LNB7VGiZMNhvl9acsqNgOnHr61XF5aODieF89MNTiVYAxsCD2zUewl1K509mWDIhZcKPSk2YfBYE+xqqyyFmxjaRxzVaCGSJ9zSk/Wj2Xdj5u5pFlDcHApHaPGfvfSmKdy8gFfWkKnogx71Psn3DmI2t0kkEgGD9cU5wVK88ipUVv4xke9KVTcQ34Uey8wuMbp14zTXJ8wgEBcdKUrkDbzUUuOGLDIPQUey8x8xKuCOP0pjIABuBA7GmxlkLFyAKDMJAIznAo9l5he49cknuDx9KbCYn3JGS7L1FOhxzsPTsacoWMMyoqlupFHsvMCMBVDAkgkdqPlKIF+b1w1MlecSqsUatFjBYmhLWLeZBuMhXHB6Uey8wuIkrtK6CJgq9GNK0ZIABIPWj95FESAxYA8HvTbaZpRH5g2sOGo9l5iuyUKSAWXI9c01o1YFsnaP4fWp9q5Ko3HtVa4tm81HSR/l7Y601R8wuxrvEqYfhf7pFVJIkMm6NiMds1bkVpCfMXjHWmuscSEkHBGAQOar2XmF2UjZxEETR8Hkc1IluixKFYcdjVkKksaZckj1pTGqFio68DNHsV3HcypVXBDQ7w3U1mPotvLOJYt0cgPTNac1wFQMVIY8cVWmaQ/NCQPrWCfRsdrse9p8vEjn1rK1y9ttGtGluZGYsPlX3puo6y1m22VcoBlmQdK891i/fVL1pZ5WaFfuA1rCMY+9N6AqdStLkpK7KF9qE2p3Ty3DOwJ+6x+Wm+VycjHpTDNbo2TIAtRyarZxkES5x6V7dOouROOx5VajKNRxnuicxAnNIYAaqtr9gM5cnPtTG8R2AGBn8qt1E+pl7MtG3INKtsazn8S2faMn8aZ/wAJTar/AMsjS9ou4KkzY+z9OKTyRnpisdvFsBIxCajbxZCD/qRn60vapbsfs32NprYlyetI1q2BtrDPi1d3+oGPrTv+EsXbkWx/On7aIvZPsbH2MscnpTltsPWIPFhKcWbH8aafFYPS0el7aIeyfY6IW4GS1NEIDdM5rn28Vv1Foce9IPFch/5dD+VHtY9w9k+x0ZhAGdtAiBwccVzg8VTZ+W2b8qP+Eql5zatke1Htl3BUmdC1vtxuz+FDWwbBXdxXPDxW/VrN+falPi3aebVh+FP2y7j9kzfaEg0hiycHNYD+Lkz/AMex/Oj/AIS2M9YGFP20e4vYs3vK5x81NMXz/dz9axP+EstsYaJhUieK7U9Y2UepFHto9xexfY1/LwSAOnvQw2jlDg81kr4oss8qw96kPiTT2wSWzQqse4/ZyL/GcAt+dBwOhcfjVH+3rBj94g1KNTsn6SDn3p+0h3F7ORP5rg/JKy4/2zViLU76M5i1C4HsrVRF5ZklRInHvQJIGPyMv4Gq9172FaS2NqPxLrcYwuqXAHuavWvjjXYDuN35o/2xXNAp2cfnTWH+2TQ4U5dBqpUh1O8t/ilqUQH2i3hkH+yK2rH4q2Zx9rs5UJ/u8/pXkci5ORmkC8c/rWEsJRluarEzR77YfEDQbpebwxN/dlXAres9Z0++Ae3vYZPYOK+Y32gcgUiStC4aJmT3ViKxeXQ+yzSOMa3R9Rzy4+536YqAys4KGPaQM59a+drHxFqlm2631CcFegJyP1rpNP8Aibq9sR9ujju17k8HFc9TL5x1TN4YuEtz2fy9yth8nHQ9qI42XJLBmHXFee6b8TdLuVC3UU1u5PXqK66y8Q6ZeoPs19Ccj7rEA1xyozhujoU4vZmzEPm+YYJqyyrgBulZ8UmVz5gIPQqc0puvL+RmIHrisy7FwFCNp3KlKsaAYUMPeqTXC5JGQT0pI7mTJBOc0W7gknsaHHTkj1pGiUHdj5TVRZHK4bpT1lZWznijRCsSGMo3yEUxyVYk9+uaRpN3zDqKhmd2ZDuAHOaQ0V7qYrciPyGMR/iB6U8y/LjFPASWM7myQaSSJcr5agMOvNMegxTJgAj8aJQScqxBFVxORcGLaSo5zVncGHPUjkUWQOJln5ZAp5PSqriZJHmmlVIFUsdw4FSRTNtAlKpJ7da5L4hjWRpypokLXfmNiVc8gY61LbWiHDllJKT0MXxT4riLi105cmU4eRuhHoKw75JIbErGSZWB6isKzt5/NEuoqVnj4CA8Kc1sy3xmbDkZAwDQ8DWq8rlsetDNsHhYVKdFa9HrqYCaBcTIBNOw+lW4vCsHV5XPGDWkZ0AyDk+masRTrt4zXt8mnkfIucm733KMXhjTwBv3t+NSp4a00N/q2P41fWcHoOanjlB6daOVdhcz7mcnh3TlP/Hvn6mpV0HT1IxbLV8S81IkwweM07eQ7lL+xdO4/wBGTP0py6NYZ/49Ij+FWxJnnFSJJkcdaOULlM6RY54tYx+FTJpVn91baPp12ircb4+8Kcsgz6UcoXKo062AwkEf/fIp32C2x8sMf/fAq4Hz0GKVgo6GptqFyh/Z9uQQYUP/AAEULp9uvSBM+6irvJ6cUoVuMkYqrBcp/YIcZ8mMf8BFILGHg+Un/fIq+qk5FHlNj0osFyn9jhY8xqMf7Apkmn2z9YYz/wABFX9khIGQaGSRSNu080WQXMz+yrMk5tYv++aP7Ot0GFtocf7grV2SliSFFRtC7HJ/Sq5UK5mHTrdj/wAe8IP/AFzFK9hbsMPDFj/rmP8ACtURkJlQM+9MIk7Kpo5V2Fcwn0HTnPNvH+VRyeHNLcc2icdxW+28dIwaiZpM/NCT9KOVPoFznT4W0xgR9n/WoT4S05TkRP8AnXSNIQw/cuKTzh3ien7PyC5y8nhGyfJUSIfaq7eE7cDi5lBrrjcRgE7WyexqM3EJHQZ+lHs12FzvucZL4UIPyXb/AJmov+EbvF+5esT7mu3DwH7xz+FIY0LZUpT9mkHOzgn0fV4ztW4BFNFhrKD/AFitXdtGD12/hUTwZ7UcnmHO+xwjf2zGcGMMPwpPtl+qbZrUnmu0e2OeB+lRSW5IztGaXJJbSDn7o5H+1njx5tu4/ClGrwnna649RXSPbAZ3KpJ9ulU57CI53opz6VfvpbhzR7GQmoW7qcuefWnJfQI24S7T2IODVt9NtSOYyKrto9sTu2nAo5qnkxqUTSstfvoXVbO/l3dlDk10mm+PtfgcRTv9o9FkXBx+FcZpcWn6Vq0N3eg7V+4B6+p9q6bS7w311dXRETQiUiF1H3lrgxdVUaTlKOp6mWYR4vEKlGWh6Do3xEs7mNf7Wt3s8fx4JWuktfE2i3m37NqEXXucV5jMVeA/Irf744rl9VfT4HBldIZP9g4FeTSxFGr8SsfQ4vI6tBc0Jq3nZfnY+i4763uJNkU6Mx6bWzUx3gBSDj1r5otrm5jJm029lOOjI/IrTs/FfiK1kBW5nkx/f5FdioQkuaM18zxJUa9N8rpv5a/kfQbyYZUQ5cnkGmT58t1wS/YGvJ9L+Jd4hCa3aZToJYxg16LpWsWur6fHdWU6MgHI3fMPrWTpvo7hKM4/HFr1Vi1BHMIysvy57rViNNrbUb5/eoRd4QEd/WpbecynOwKw6e9RyiI7hxGkYYtlifuimyW7eaHZiU9BVwSIJgCqlvSop5Bk/wAPPejYHIoxwNySihR3qtNPCsNw+MMiEnd3OKVLkCRI0BKgc571ja4ZDpOpyvIDiI7V9K3jTu0mzKcrR0PHruU3F3LK3VnJwPTNNDRhvunNURMNo35HpURnIOVavaUEklc8zV6mrvUH5R+dSrcbTjisIXaM3JIpyXQX7rEijkT6hZo3luzyAanF0AvDc1zYu+eKlW6Pc0eyj/MFzpYrzd1qT7So6NXOrdlRyc05bksfvGj2Uf5gudLFdIepqdJVzlQMfWuVa6AGM9au21zgAE5GKTpLpILnSpOPwp/mdxXPx3m3AJytWkvQR1wKPZf3g5jaSWpQ465zWJHfqxwDVqK7Q9Kl0v7wcxpiQNT0OWHpWcs/PDVKlyAQC1Hs1/MO5oqQDTgRnrVJLhSefzqWOaPdRyJdRotgj0p24E9KiWZedv60qyrnmjl8x6k+AaTYKaJVzTxKntS5F3APKy3AyKd5QPHl4oEoxgU8NnvRyLuFxnlr/dpPLXPC1Y+XHWlDKCO46U+SPcNyq8J67Rio2hB6KK0CFPBA45pGSMDIwDRyx7i5TOMK9PLGKje3jx/qlrQAHTApGXbQku4uUyzaxH+BBUL2cZ6IorWYZ7VGcbcAc1aS/mE4mRJZoOBx9Khls8jAZl9xW0yr3AqIqvfpRZfzC5Tn5dPm6pM9QNZ34GUdSPeukaJT6U3yd5wq7vxqrxiruSHGDm7RRy5hvgeY1GP1qCYXI5a2DYrtF06WTqoQe9JJoxAJLpmsZYrDrRyOyGV4qovdh+RwUkzj78BX8Kia5ULjBA+ldzNopKZyrH0FY95ppQnzIRjPpVQxOHlopE1ctxVJXlA888USxssCqxyMnFavhy/mt9MWOMjg55rI8WhP7SEaDaqL0rV0O1hfTI3b7x6modKnVqOM9UTTq1MP79J2Zo3OoXMqeWD5SnsKxbnToiS8kYkJ5yx5rTktFUjZIxqrJFKjHBJWto4PDxWiQquNr1v4kmzOhgktm8y2cx/jwKkk1vU7YYISRfpUx46g49Kq3I3dqxq4GlI2o5jiKNrT0JIvEjyELcxIB9KNL1i4s7wvYStEc7hzxVJ4o2IyBkDvUTxBG3dPpXNRwcaT3NsTmdXFQUZu9j3/AOH3jKHXLb7NeyQw6hGOIz/GPWu7EgALEqABnpXyl4fvJbHXbO6gy7CVQQfTPSvrBCZIUdlTEiKSB05rGtQpp72FSqcy1GzJJNFutSofIOSKeJP3hinTLY+8V4pXyw2R4DDiq9pFcIHSeTOWyO9ZqlB7s0uzLurlEHyjZngNisHXYmudMuVS4RCUIIYH5zjoKmtomAWKa7E7k7wOm2pZhD5kckyCQg7gM8ZrlTtK43sfO80jW88iOx3K20qexqOWViM8/nXXfFLRVt75NT0/545yRIgH3W9a4FJC6kqSSO1d8a1zicLMt/aDnOKBcEA8VT8ylWQHrTVR3sTylxLgn61Mk59azi46DrTkc+tV7Rhymj9obGSc81MtwelZivubHpTlmGMGtFMmxqeduYc1cjuNpHP4VhpKFPB5qZJz361amhNG0LrbwQcVOtzwOc5rBE5LkN0qeOUZ+U9KvnQrG0k+x+5q0lyMZDVgrKSc5qWO5YHGBRdMLHQJd7mABP1qzFcZPzGuaW5Yn0xU8N2SeT0pOMegXsdMl0OBnirMVyAcZ4rmFuvmHNWUuueDUuNg5jpRPnH9KmFwAOtc2l7g8VOL5TgGlYdzfWcE9akE4rDS6FSLdAtjNDKubgnBHQ1IJj2rGW5Hb+dPF0RUspam0spwDya29F0yTU7eeWOSOJIupkOK5GO7zgCu38P2Mmp+E9tvN5Fx52/JGQeCMGvPzHFPDUXOO+hvh6SnK0iQ+G9REIkjVJUYZDIc5FU7jSL63BMlrLkDPArqtKsNRsdMSJNS23HJOU+UH0FXlm1mKUv59vcoVwQRivBhn87+9Z/16Hd9ST2POpFaHPnI0Z7bhUZcEZzmuh+Idwxns0ZI1YplgtcaZ1BOBjnFfSYPEfWKaqHn1KfJKzLpYUmVX5uoqmJx3pwmB4rpvdGbRMSrseMU3IycDmoDJxxxVrTlWSVWfovP1NRUqRpx5maUaLry5Ik0FmzpvlG1T0FWUSJTiONc+tS3Fw0xDEYxxtFVy3mHYD8q8nA5rw8RipVHa+h9pgcspUIptK5KzqCQSM+lVpAWbGDWtp+g3F6PNB8uL/aHJq/JoKQKMSljWVPDVamiRtVzLD4d6s5ORHU8ErUE0rrgMA4z3robuy8snHP1rLu4EIAZQuR94UTw9Wlq9DahmGHxXup3PFvFltK+uznyHIbhcDitzSLR7TS4o5Ew57EV3k1kGkTCgkDgkZ5qtexLcxNGwUTJ0xXbg8w5JWn955GYZDCcJVKL17HJSbSzYxVNwN2c5FaFzEImIIPFZ8vTivpYNSV0fFShy+7Yr3AyD0xVCVRzV2ZuKpSHg0pERXQqSjHNV3IB3Z/OrEhyMVTcjJ3c+lYyNUNV2DZVtrZzkV9JfC3U2vvBsErSNJLG+yTeetfNIB3ZA4FfQHwQgkXwZNJcLtjll4J+lefiNVdnVh97Ho7XcAdU8yIM3QZ5NSLIpOPQ8nFUnitUeMtEhlAG1sHNXiFEZJyfUAd65rI6Tg5Fea2Jt4Vz37E1Bpxku0uY57V1EeAhyea0pVMrRiEFZF5PvUwnlGV2bGzjnjIqLsDKtrDdfeXPJbtCf+WbKMnisnxH8MdJ1OItpoNhdZJIU5UmupvNPtllFyYsTAZGDnNS2N35iHduGR/EOlQ73ugcUz588QeA9d0bzHltvtEA/wCWkRzXJNvj+VwVYHoeor6l1LNzCsSt/o8mRIM4/KvKPEnw3knZ7rRpvMBY5Q9a0hUf2jOVM8y3DIqVSMZq5eeGNfts7tLmIDEbgMjFY2+aLPmIRjrkY71qp3M+WxeDZbJp/uO9UI7xWOwgg9eBmrMdxHt4OSffGKtTI5SwCPxp4Zu3aqoYnDZ5xUsTHGcEGtFJicSdXbdk1KZAR8vWqe/saer4qlMTRcV29alSQ+tUg+BxT1etFImxeEpzzUqTYxjGfes7zcdelOWRSw9K0UibF+W7jhjaSdsLntU1teRytvt3ytZF1GtzAY3OB2pdKtvsSsN+4Mc0Rk0xWOgWZg2QpJ9ql81zhSu05zmsLUpZhZP9nkIk44FV9Av7idZFuWPydCaftNbBY61ZyO9SLOc5zWMs5PU08TnOAa0smK5urc471L9r4rCSbH1qVZ2PcUnDsLc3o7oEYbjNaVprN1bACC6kjx2ViAa5TzsgAN09alS4PIyBxwayqYeNT4lcqE5R2Z3kPi/Vkxi83EdAwzWhbePdQj5lSGVfQjbXnAuBuA3DdUi3LBm53Y7CuGplOGqPWC+43WJqr7R1+s63Jq999plRUbbgAdBWes3y8NmsRbtlZcnpT0vOoFddOgqUVCKskZTm5u8jb83d1NAlPrWMLr3p4vAAMnmtFFslysa5mznLdOlbmnfLax8cnk1x/wBq+UAYzXUWs22GMk9VBry8ybjTR9Jw/SVSrKT6F+aQqBs4Y9a474g+LzoMCWlngX0gyWPOK6iW4BlUkjn0rwT4gXsl34pvXZjtQhFz2xXmYWHtJ3fQ9zN6ssNQXLuzubX416/BbQxPFbOY/lZiMZFW4/jdd/aN91ZxNDjkITn8K8YaRwrBTnBqEsdgwPmr3VVcVZHw8nd3ep9KWnxO8Pajah7qd7WQ9VPNaula3pGsArp+oQS+qNgGvlMSMxPJzVmyvJrSVZ7eV4pBzuU4zT+sX0krjg3CSlB2Z9S3StBKV53AZB7YrMvAEuElX7v8QrhPhd4jv9Xu7i0v7lpgqb03dRXfNg4z1HWvAxMeWo+XRH6Jl2I+sUIzfU5/XIcOZP8Anp1rnpQA23sBXVa7j7ID74rk7kZY19DldV1KN30Ph8+oxoYpqO1rlS4YEEN0qnMOM9qnnK87utVHYgE9gK9FnjK63IZeVxVKQKuSTg9qtTuPzqnKyg9MisZNFoZjPIbk9q+g/gNvl8JTq84mCT48s/w8V89ptPJ6k4r6C+A8aJ4QllGEV5zk45OBXBW1R04d2bPTUjQnkAn1FJMsir+4Zdw/vdKWJw6/KR9cVXvtQtrQET5IPHSuazOg5O0iuIpsvKC4HRu9Pi+0Ncyb3dmJ3bSnyr7Zq4fs0zid4yRnggGppHWT5ICy715OOlaOEO47mW1reT62t2kkiwpHtKE8Z+lOWVLe9W2O+WSUZPHA/Grc7R6fYFpbhyw6gelNs5o3UtDG7sw4cr0pezhbcOZlGd4oYpAqEkZJGM0WtuqTQxr96UZxjpWodN3SI4ZsKpJ6cmnwYlSSbyyknbNS6UH1L5mjOubZkA2gMgzwR1PpWNLolteWipqOl2+STlAARgnrmuquGZAzKAWC8expIFaRVEmPMwMiodKC6jvc89v/AIWaFeQl44GgbsY2xgVyer/BqaIr/Zl9w3OHB/nXt8s6QI4ZSTnAC85qC4V8rMm5ScfKetCjGP2hNJ9D5n1fwJ4j0dnLQ+ei85jOeK595bm2bbcQuh9GWvru5hGxdjknGSCtZl7pNpqEa/a7GBl6Bwgya0513M3TufLUd7G4yeP5VOH3Y2YPfIr2fU/hVoEshZPOR5SSSpAx+Fc7qXwhkg3HTNRJ2jISRT/Oj2ke5DpHAI52A4OOlCkHvVzVPC2vaOz/AGi0aZBzvjBIrKF00cnlzx+W1aRnGWzM3TZb3c+1OzxgDioFlQ8bxViLlcA7lreLS6k8rHrJuwCuaeXAIxxiofung4oZuhrRTj3IcWWg3VgOf50vHVFCg8nFVo5OmelOdiDntV3i3e5PKWt5p6SEdOtUPOp6TVSce5LRopKc804TDdgnBrOM+D60plG4HaatOHcmxpGUE53VoaJazavq1pYQHDzSBd3oKwBJzztrQ0XVpNJ1S1vrc4kgkD8Hg/WlLla0ZcFrqfQN38ItFNo1taXzrqnl78F/vEe1eIXqy2d7cWs+RLFIUYDrxXt1l8UPCFwE1W6d4dTSPDLtOWOO1eC+INYOsa3qOpfcFxKWCngisKDlF2kzSqkifziE5O3/AHjij7QRzkMvqpyKXwtcWJ8R2I1WJpLRjtKerds1N40awt/ENxFpqeVGv34h0U//AKq6VOPcx5WRrdZp4uMgc81jx3FP84r8x6Gr9x63Fy21NgXB4wea621ujJZRuvTaBXniTlRnua6Pw/qIkhe2f7w5FedmlKEqfMnsfRcN4hU8TyT+0dHHIX+bJOK8Z8bQ/Z/Ed4snIfDrXrMUpXKHvXMeNNBXUUW6iGbhBhh6ivDwsoUpXb3Pqs6wssRh7xWqPLWUMMq2BUax7SGLHirs1rtkYbdjA4K+lQvbOVP7wZ9PWvW0a0Pz+cZKVrFVtu48gZpAoBwD8p4FSi2kxkhaWO1mlnWOJCzt0x9ah2WrCMZydkeg/BmEpqV9cdo4wnWvU3JHXOSOa47wRpv9jaeIdmZ5SHc+ntXVfaeQ33u2K8ut7OUrtn6JluFlh8NGnLczvEBK2Cg9c1ydy45Ga3fFl4ghSAH5jzXKvLwDnJxX0GVU4Qo+rPi+IZqeLa7L/MZI2QV9apykgMD6YqeSTgk8Gqcr5r0JcjR4TI5j0qtJg8HoakkeomGV461yz5CoiQxs06rGCSxwo7k19VeB9NbS/DNlZPGsbiMOwHqef618z6BJHHrli8w3osyfzr6stxGyq0ByXwRk+1cs4wZ20E7XJVM3nMAAE7HNEiPIm2Ros+4zRHNliHwXzzip18oNuKZYDvUctPua3fYxbqd5IytltCg88VHYyTR+dl0+UfjTpJIorbfLHtVhtAHBqjFaw2ryzNIzLIMYJ6VyKWhT3LjXUEyLHNbvIzHGQOnepIZE8xvmZAvAzwKltvM8sFdi5+6CKq/YZp7kSXsyvAv/ACyRRz+NQUzWU7lGA20ZHSoY5VaTyUiJVVzvPr6UlsShUxyMYj8x3HkVJ5zKrsUIHbHegQ2RVSE/Llm4z6VTG6BAM4I53Grd3dxwW6SNGd54wTxUEbpdHYyhiOSM0rAQtdEFTFGsqk/Mw7VcghjjJkVTufn5jmqFtaLBNcPbxSqrcjceM1bt1PmKHf5wMkDtTaXQq5ZZUBJKFlpjopASNP3fU89KtYIU88Y6GooWRc5znPSps+oNmfNbMZBMEURhcEGkkgWWB1gBzjIxzzWu0fmqy4zux2p6oqcFMH24oFc5N4r42UVutuDNI+Mt0xWdr/hnS5oc3+lJOx4zEoU/pXdSWySbS275TkHdTjGSCxIOPQUhHh2ofCyx1BAdPjlsWPI38iuQ134d+IdFYPbqLyI/xRDp+FfTjweauSML37UxbdVUhOfSj2koj5Yvc+Pp3urWQx3trKjDruQgU5JUbBRlz6Zr6s1XQrO/h23lrDLu9VGa4DXfhLo14ZGsme0lPPynIzVwxGtpIzlSXQ8SO7dnGc0Nk9Qa7LWvhZr2nB5bCRbqFRnrzXHXdtqNjJtvbWWNem4qetbqqnsZODQ0OM4p6sSTgVS+0ozckIc45qUTL8xDDHatIzsQ4XLStkc0obdxVdSzHAK+p5qwowhORkVtGd9yHG2gHH8PH1pC5Xt1pGwRnrUMkpyMg4q3NE2J/MyckA04MWOTVMykAnHFKs5I4pc47GjBOUmiPcSA1f8AGLk+IbpwPvBSf++RWHE5aaIA5O4DFa3i2VW1y5KtkAKv/jop8+grFSOQlKf5uUGTVCOTAwTT9+4Dt7U1PQLFzzjgYqzZ3kkEyyR/eFZhcleMUK7AZyKHyzXLLZlwlKnJThuj0KyvUvLcTKfnx8wz0q2rhiFZskDNedWl/LaPuiOB3X1ro7DXoJ+JsRSdM5rwcTg3TleKuj77K89o4iKhWdpFrVdDs78tI6FJP7y1z8/hObI+z3Ebr6MK6tbgEAqQQe4PWgy5YHarEfhXPGvVp6HbWyvCYp88uvZnIx+Epy+Z5olT0UE10GiaHbae2+Bd0uOXYcfhV/zsHODSCZmY/Nwe3SiWIqT0Y8NleFwsuaKu/MteeVyofJPU09LpYIDIx2qvcnrWXcXkNuhMsiBfTNc5qWrteHy4+IB39avD4WVZ26GeZ5pRwtN8rTkT6lqDXl3LMw4PQelUGlHXtVbzSSABwBjNM3EHA7DrX00EoQsfm1Wcqs3UnuSvMQeeaikkyKTf8ucdagdtxx0puehkl3F3c5PSmSnjKnkkYpNwIK9KZtJwM8DmsJSNIqxreH4Xk1S3URb1U7mI7Yr2Cz1u4tXjaB2Ke5ry7w2GsLF5dmZXb17V1MephURJDtdhwMUKncpTszuoPF06T7JTHt646E1op4sMlwkjoFixghTk15hJNKW3lV+vc1ctpmX5kb5D19jQ6SNFWPa3t/MwtynmY+6egFB09WJ8wKFJ7GrcqKzqweTPpT8AscE++a806LlK5hSHDIzbhxjHakWJYf4nIIzwKsqWabsIumSKZPdxW8UjnjbnHFCHcjNukhVl37WGSPSqN9feVbSySDbDENodh1IqbTbsXKLK5Lq68AcYpsunpeBo3iGzOcGjqMzbG6iv0ieNg6cllYflUjQqtwk0W4SfxIB1rXitrWNI0g8uNhxgd6teT5cihUZ89wKeojDm1gDVYrJ7aXzChZQo4P1q/Czu3mMiq+B0q48ao7SqpLqCu5l5GaZCh8tArdB3pgPkIaISzcKvOe1JE8Xl7hjnofWorln8ry/LLKDk4p9s7FMKjIB0yKmzAuRNnBxzT2IPJHXio4RO6M7YwP1qSFjLGTj5ulTZisKE2Lk/dpwUKQAoP0pIxIGCoAfUGpCjmMnGWp8oys+yRiDuGOOaryOsQb+4B8zelSy2ztHkoVO71pTFsGCmSwxzRZdRECFJJIiW+QjOe1MvCQiJHGSMnn1q1PsjeNV9McDpTfKkcjuAKhxvuU3ZFGSCUzKCP3LRjg9Qap3mkWN1CsVzbxzA53B16VuW9rcMq7E3FW/ip9x5EO1rqVY5CSAo71hOtThpzalKLfQ8n1H4UaFqayNFBNbPnhlPH5VwniT4Q3mnwyy2F2bjYRtQrgnNe4arfpK4S2MoUcHArn9MXUrO7uyT50NwQP3n8Fb023G5nZXsz55vfDOv6YjPdWE6xryXx8tUbZr1pVjjtZJWPZVr6h1JIJrN7bUbiHYB0Nc3dT6ZZOGtnVlTAAjj5rqjzGDavoePweF9ducD7AYlboZOM1FqHhrULAlb020bDt5nNegavr6LeJLFaXUuDkBuBXK67qz6teeY9jBFJ0GT2q7tasTSscZPKYeDhh0ypyKYLgE+lTX9lePI0kdo4RDzsUkD3NZzeZG+HTn0xTUkyXGxv+HgtxrlihI2mVd30zzTtclMutXrgfL5hA/CpvBSJHPd6xOuy30+PcAf45DwoH41gvdiSZpMnLktz7nNU3ZEl0yAinI4xnNU2nQYNPWVW5BxTT0K5S4pHehmUdDVUzcCl35Io5g5Sxu596GbK4OP61XVzznrSeZ8/NDlcFFmhDfT24HlTN16HmtA+ILxG5ZHGPSsAvycU5WyOetZSpU5bo6qeNxFJWjNm8fEF0Vzti/Kq0muXTj7yqD6VkFyDg9KR3xjjikqNJdC55jipqzmy3JOZjmVi1LuAAGcr6VU8zPA61JFJnr2raDjFWRwTcpu8ndlrf8ALxTWO0DByTUDP3HFIkocH2q+YhJkpYlsDpTJDxx1pgf5jk8Go5n2jK80c4JCSEj5h1FWNPj+2TrHgkHk47Uy0P2gqp5Hetm0tBbvviG0mhRbYOVkbMJSNFjhGSPlxU6IyyhpPmbtntWZGsiqWz8xOavW5lYfMMn1rq6GZo72Z9zDBX8jU8Um0bkQ8+vSqES3QbA2eWemTzV2NyRsJbI9KNGCPooRZzjj3qMxkNgNyec0omZEZcZx3qq0RMweV2I6BRXl8tPuejqTZCxOd3y9OOpNVGiD5CgFO+e9WASgYQmNsHOzPNNiimeMPNtSRj2PFHLT7hqQ20DRlvMxnOF2joKuQwlTnOD33Gq1zJLGkfK4JA6c1JtBcl97c5wKFGmUNkhl+0KixJ5DZy/dT7VatoJIYyjSvIeuTT/NVVXONvQDPIpXkbKR+WSnUuO1O1PuLUbLCT8xypNL5cgjHPJPBxUyyIfl3Bieg9KjSQPceWJF+TkilaACMuwNu5J4zUIjZ04zx3q2wVt6n1pSPLPyDCY5JppUwI4kLoBuORU6RMqZAwR6Ui5XGMY9amUMX+TOR29aVqYale3fesjuGG3qPWhYZJJPvkAdaV5f3jB8p65Ip3nAIrp84Y4O3tT5YBqI0LCdXSVsbeU7VGxcXClYxt/iNSwsHmby2JCnGOhqeViXGUxzSap3Cz3I/IJjUgDk5xin3KQadavd3HygDOPepoXAkQEgYPSuQ+LWoSiygtYCwE74OK8jH11zrDwdnL8jooxb1aOd1rxfq2r35stCyGJxlew9a7eTQmXTtPe5meW6gX94394ms7wVpEWnWalYP3zgZfHJroPEOqRactrbyMAZn8sZPfGawq0qGGqQhDru+rNVKUkzn7yxYf6ohe/ArHvLJ9v7yVif7orqJWLKcKc9KrvbgMHkUk9a+gjGktEcDlLqcvLosKW7S3XORkKax0sVvLwJFFhBzwtdZexTXsx3YRBwBSz7dOsWaPaJMYya1UabIab2PO/EtoLb5RtXPyquOSa828UqljOsRbEvUt716LqFz5N6JnQ3E0rY3P8AdX6V5t48tmTUX8zLcg5PfPpRL2VrISU7mjp15qOkWzajp5G5lxKjKGUj1wasQarb69cwQ32jWtxLK2A6fKT6jitvw9p1yuhRrqMLIkmERyOGBHSsSx099GnvbkqUmVzDBn0P8Qrhw1anUqOm+hvVUkkamq6HoV/ENG025exhhk3Nu5SR/Umsub4O6vNCZrKe1njJyChxmo7awupJdkZJ3egJNevfD/TbvT7ORp3lCsowj/0rrqezS0ZChfc8B1b4e69Ylg+nyHHQqCawLjS7y2P763liPoUI/nX2ennbFwFb681UudOhunb7RaxPj+8gNZKrFIHT7Hxi5lX73B9OlHmSgg9q+tL3wfoN4pW70+AseMhcGuZ1r4R6FJGz27yWxPTHIpqrEPZM+cRcSE9QPemSTSD5gOfX1r2K4+Ds8UDSxXqeWcnLr0HvXmeqaNcW128e0lUyNwHBx3p+1iONCpJcyWhkrdSF+lTLclm+7yKvWGgX15b+fb2s0kWSAyqSKe2g3sDhZbWdGIzyhqlKL6mLi0Z7TO3ak82QqBjgVPJZsrEEMMeopDbuvDZx6CrVhESStnBGD61NCQCSTnNRmE5wM/jUscOAex96tcpLbHEk4BANIiFJCcYUjpTkt2XJZwfpUmAFXJyM9aPcI1IJeY+BU1tB5owTU6ojNjP4etPSPY5xTXIDuWre2EMeY1UnvVqGQbwAME1Rj/1gO5gMdKtLNtyuPoa6IypkWZeMy4zJ8qjrilt5fNz9nLEe/aoYgkmAp+u6rESGKVTAuc8EVonBbk2LBMioDHJkj+GpIZ7lR5gjVk7881YtbUM4MilSD0Fa0VqshEcacN1xTvTHGLPdsrt2uxBPNUEuoby4McU7gxcPtFW5JA7uIJDx970pN0ccR2oFDdSB1rwj0RLWCCJi0eHLdWPWpnDBmIQMF96ZbeWRujwAOnvUsDTCdlaNRH1BFAyREDxCRiCc520yRdxYhuSDU3LNyVz7VEwJV1ckj270AijHp7vfQ3TXBGxSPL9c1oIrI7bHcg+tMjkG1f3IRF6MetTTAsiBX2A9h3oGQMT9o3QEEEck9jVi2jAUu4Xf6nvUcYCzbTyPWnyCRlO04I6UCHySxrMVdlGcdKcQJI/vfuqrRuwjCzjJz19KsxPu+ULx60DRHHv8lgmWOalZ3YhtzKw+UgUy5eaKLdGM/N1q0vzBW3YY9aAKEGmxQztLmSSV+zuSKmaXZIsMcIVjzkdKtybsYAy/rUbjYh4zmi4ETN5rCNTskA5YVYQSYAY7mXp71BkeXtA2e+Kjik8sNmYkfSlcfQuGTMqvt5WsvxlpR1fTFltxieNg61ZW4RZMH7o53GpRdokoZZQdwyUrx8zw85SjXp7xOihJfCyPw1O01pCHA3INr57EVw/xRtpdV8X6HZSyvb2oJfzF9elehQxwyuZ7UhJCDlPeqt/Y22qpANQi2XMLhkb3BryZZjF4inVqK1tzeNLRpHP6ZdtaXp0vUwRg4glz98e9bU8LKm0k+xqC+8Lx3TStLLJK78jnhTVa2tfEGm7I0RNRtxwPMOGUfWvo6OY4aS+NHHOjLsPuhHZxZnbc55ArktedrwYjDBTXdz6S17GGn/cM3UE5xVOXR9LslEl1cbtvXc2BU1s2w1PaV35ChhpyZ5Pq2jXV7eWdhYRvJcsckgcLXU2Pw1sIHS+8S3H2iSIZEWcLx61p6z4+0bRw0enKs078BYh3rhdVl8Z+MWENpbNFA7bcDjg9ya8upi8RitEuSHVnZGlCno9WbCeIx4q8dW+i6PBG2mwJ+9IXhQPSsq90mLWviFdafeS+Xb2q/IqdzXaeF9C034Z+HbiSeVJb+YFpZT97P90VF4H0OS7W61fVUPmXjkop7Dsa1y2rzVmov3Iq1+5nXS5UaemaBpulohjUEAYDMMmtZkU4UsGz0xUkNo6AhJg+D90jpSpHdBsbYsN6V7aRz6DEDhCqjpT22qPlJBPrTxFdKjAbAajEE7riYj/gNDdyWysyHeWdgcVUeFru6TgiMHmtRbVFP7wEgdM1OoXIOOR0pFKVjOv7JLi3e2bd5cilTivOtV+GsV1F5Iv2jgJ+cbBux6Zr1IhkOQnXNRGMYXdyajlTdzWliJ04uEXozB0bSbXSdOisbOMpaRLhWI5Y9zT5La2uWVyFdh8hUjrWxMMOQyjHbiq5h2uWjcLu46U+VJmfMc3e+GdJWGQ3VrAyyHsMEVhSfDjQ5kDeXIgbowc1299paXkQFxI6hemDjNPtIDDbLFI/yoMDPWq5rbByp7nmOofCfT3XMFzKuT1bmsp/hTIxxb3gwvqor2YwRyqMuQM+tPjtjGYzGN3PrTU5EuETwK8+GmqW5PlgOPasC58H6tbyYazkIB7CvqCSEu20jio2sE44H1q4131JdGPQ+VZdNnt3ZZY3U98jpUX2d8Z9a+m77w3Y3rulxbRsG6sBgisOX4f6PGC8ccgfPHPFbRrx6mMqL6HgBhI45zQSVdEwfcjtXuVx8PdPeTKuwyPTpVSX4caesbPNM4J6YrSNePQzdGR5FahBIVB35/St/TbcNII1Ri1ei2vw202BlcSu6kZxW7F4RsoQGizkEGtHiVaxUaHVnJ6X4YvLhEdk2Rt/Ea6y28JxW0alJcXAOQxGRXRWcOxcZ496neN1IKjPNcrqNs1jCKJTDgY2qqMMlhxVa2u4pt/2WZHSM7SMdKnuZ41cQAkN6HpiqllHZRROLdRhn+YL3NCg7bBdF5EEkbbcKDRbRGJfmk3EdMU8KYA2FIOOFPpUck7bVKrs+oqeWXYdwubyKziZpwHIxkAVymoeIb0asRp1mz23ACkc/WuqkjEuVdVYnk5oSH5gVVQMYJC80csuwEKh7qFGk4ZgCUz0qW7LW8QSIb2wME81JHbpbxluct6nmo2RQjkk5xT5JdikS28oZAGB3Dr9al3s0hIHtzVa2SFhkO+734zU/wAjs0cbneh+YdaOSXYVidYsK2cH2qaLYq4Y7fao4gI87jknkGgufNCmEvnvRyS7CbsI8rCRggBjPY1J8uOSFJpJNkbnPBPalVd33sZP44o5JdguSFh5eFY7h3FRonnYJYgDtQqyFty4wv61NDt2Z280vZvsFyOPJLZ3ADgA96a4G3GOe4qxKuRyeR7VCrfPkjg8UOEuwuYa0MbQIXUMD1qs8MXmqfKVWHCkelWJ90EIRQWZj09BTsGWVd67VUYB9ankl2Ki7kYhbzflZYyOQR3p0l20fE0Xmp3ZRzU5XAJGDUiL8uAvB715uKyqliL3Vmb08TKOjKAurJgAl2YG9H4pJYbmUZttUXB9ealuLG3uGIliVj7iqg0WzYYWJkOedrHivIlw7Uj/AA3/AF950rGRe5Rv9F1m5jdIdaEe4feCHiuWuPhm12S2teKLyZByVV9tdw3h62zjzrgKR2Y01PC+mqPm8+Q/7TnmtKeU4qnpB2HLEwfU5K10fwZ4bIbi4mToZG3kmrreJ9SvAtv4e0iVQ38brsWurttA0y3ctBZRA46sM/zrREKpGPLAUY6DiuqGTcz5q0m2YyxSWiRxFp4Rku7oXfiS4a6lX5lt04jQ/wBa17W+nTUDbC02WijCkDpXQqCFwSC3XBprbDlGAr16OHVKPJCJzTm5PmbK7AhGdNgXHTvVUK0iboQN46Zq0lvHHJuAY7uxqdkU4IGM9gK15H2I5jLsJo7qKV1YF4zhlx3qco2d7Hg9hU0aRQ7khRUB5PHJNKqCP5mJIPGKOR9hcwxVAxkZz60yRFMmFyKssAwA7A5zTAd8rZG0rR7N9g5iIpkgKwG0Z+YVHLggHYAKmuJjHtQ4LueuKZI5A4Iz0A9aOR9geu5XZWLFiD04qGVMkKRlSOamCSE/McEnpVS9ungZI44i7OwGQOgpqm+w00iQxgHKIMdcGqjI0xGPxBq95coZWzwR0oywOQBgfrR7N9h85ntbIELNGSF9TUkYjWPeqNhegzVkB5Mkrt559KdH2Ax7ij2cuwcyGRl5EG6PYfel59DgdBTHZpQVwyr1DE0snneQvkOGb+lHspdhDyMp85I3DkVVeJnRR1Gamy0YC3Eykv0pzKy4UAkdsU1SfYLortboBs4HPHNQSRYkDMmQvryDV9lYxlQF3Hue1Miil8pleVSO2Aafs5dguiEmQjdGqBe/FNaRchdx5qYQbVwWJzSeXIJlQKpGOtHspdguVyrNja461cwHiIyRt702ayLLjJBznIqRF+UgN045HWhUn2C6K7zB3LHbGh6Fh1pqQYw0YUDOTxTFlQLI8/IX7qkcVaidtuCC27mq9rIOVDS/lOXbc7tx7Cq2o65DZGPerSseNqrmrUcrmLMiCNx69xUW5TcqAqkkdcUvaSC3YtLKJFDiMq7jkelEDsMBOvSoYt4JLvlegINTDcZt0W0DpjFHtZBYbO+ZAE+Zx+VK5LZwgPHahFbJG0Ag8kdTTzFu6HaaPayGkihPFM3zKu0gjHNOS4Cb4REVlbJeQcVakZ/K8tQpcnAOOlOe0dgqzDgjDEUe0kGhWM2y1UqrSyDoQepq9Fcu0Slk2seoB9qjtbULC0anKqflp3lMOo59RR7SQuVMiKlpVZZG2jqDUwmdUIjiJJOOOtJtPksAAuOpNR2g2SM8jtnHy4PFHtZByouQr0O1kPfJpQVAZkRgAe5qFHkuZiSR5OMZqy2FIzhl7jNHtJBYmZwcBuSwz+FQySgOEU9Kc8qKysqDJ/LFUruCV1Mlk6iTOfmo55BYvl1QKCS2afnPyoMg9TVazk8xUZm3SYwQOlWU3feUjjhvrU88gsnuLjA2sOBQkuwnnjtQHZUZSV2nuagmVSw5yBzx3o53fUfKuhOJAGLEU9GViTuxntXO+Idcj0uBHeKSWZj+7gTO5z+FaWmXL3Nuk00RhcjJQjG32pc8lswS7l+M4JBfJFTBv9oVVYqzBRkE87v6UpwkbEfM/YU+eQWRYJPQd6azsnGAcVG0pGwIDn6VHJJIZMNgk9DjFLnn3DlROzM8y/KoGKZLKoGdhz6imt8i/vSGz6U12Kp+7bA9DRzPuFhyXICqpzke1NW6HC5OTVZ2Zs7yM9sHrTY/vEh1Vh29arnl3FyommuAku52URjjJ9al+0/Ltxk9az763RrPLOpBcMc84qxGxlXeq4JOKPaSDlSJmlL4dhtApPMk3KwX/wDVVdTMzyROvyqetWmLbht547dqPaS7hYaSN53xlgehqJt4K7EHHrVlDiMhjSSZ8sbcc/nT55dwsVkaThpApzRL8jAtjjoBUJKrc+WGxkcgn+VPz5ScKWOckk5wKPaSFYdGXE2QuQajlQjnqPepQwDDEnLc0rxlh8xyB2o9pLuNIh3ZXgYUVWliJO9TgVeI+QY4GelVp3CqQpXd2GKXPLuFiNztWPE2SeACOlTxOY0dZAC3qBTId+V3BWB657U6aBXcEysrAYHPFX7SXcVjP1CwW6QGQvuH3dvarEENxBGiqC2P7xq1FHJFEGDhyT1pT5hTcPmHc0vayCxUvftUgDW6KGHVT3p6yyFAzALIOoHSrnlsVYhOCoxVd0Y5G0KoHNHtZAkNkKFN38fc0xDH5gbOSO9DYddgHHTNAijVccgjsKftJdytCVpSWOCTj0qGTdvyueR0p/mDyh5aYPfFLkFRtJ3A9+an2k+5NiirebkOARn0q5GxYqDjr2oorMGNu4VafLZ5X196RIURMqOelFFSxrYcI1j/AHa/d3GpoQFWRQOAM0UUIGBQDMvO8YpspzKuaKKokmUBrhUIG3FEA6gkkZPWiigoANko28bhzT2JUjFFFBQ25QTJsf7pHamrEqLHGB8u2iigBLeJVIUZ2lqlWBBI+C350UUCK8ozjJPB9aI5WC7BjaTiiiq6AXExEI1jAAI5qfYEKhejDJooqQK18vIXJwaeFCR8dlyM0UUDQ0EeSXKIz43AkZIPtRGd2wEDB5OKKKUQGrIzXhgJ/dhSwHuKXzGRXYHkUUVTAktc/ZQ+5i2fWomkaUNvOcHFFFAFny1+z9+aa0ajaOaKKlgR3X7sEpxiqq84kPLHIOfpRRTQC2qK8UoYZHXmpJXZJIVXgHmiigTLbnagYdSeagicm5k54HaiigCWTmq10SJIxk4ooqhEssSMPMZQXToaauGTJA5FFFA0Qy4VNwAyKczsVUk9aKKQhsshjQlcfjURAkVXYDdRRTGKihFbb605TmbBwRRRTAswqGj2kcZPSmsPKiwnQ0UULcTGl2CgBjULEkYJJBoooYEiAKuAKifl80UUDI7tzFBEUwCx5/Okmby0BUDOM80UUwP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Camp D'Altitude portable hyperbaric chamber.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21872=[""].join("\n");
var outline_f21_23_21872=null;
var title_f21_23_21873="Jugulotympanic paraganglioma of the middle ear";
var content_f21_23_21873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Jugulotympanic paraganglioma (glomus tympanicum) of the middle ear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Picture of a left tympanic membrane with a pulsating red mass occupying the inferior portion of the middle ear space. The rest of the tympanic membrane is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bechara Y Ghorayeb, MD. www.ghorayeb.com.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21873=[""].join("\n");
var outline_f21_23_21873=null;
var title_f21_23_21874="Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)";
var content_f21_23_21874=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"MELD_form\" name=\"MELD_form\" onkeydown=\"clrResults();\" onkeyup=\"MELD_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <div id=\"calc_equation\">",
"      <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"       <tr>",
"        <td align=\"left\" bgcolor=\"#6c9a9c\">",
"         <span class=\"medCalcFontFormuli\">",
"          MELDScore = 10 * ((0.957 * ln(Creatinine)) + (0.378 * ln(Bilirubin)) + (1.12 * ln(INR))) + 6.43",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"     </div>",
"    </center>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"MELD_fx(); minMaxCheck();\" onchange=\"MELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"MELD_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Creatinine",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Creatinine_param\" onblur=\"MELD_fx(); minMaxCheck();\" onchange=\"MELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Creatinine_unit\" onchange=\"MELD_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Bilirubin",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Bilirubin_param\" onblur=\"MELD_fx(); minMaxCheck();\" onchange=\"MELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Bilirubin_unit\" onchange=\"MELD_fx();\" style=\"width:105px;\">",
"              <option value=\"100|0|gm/L\">",
"               gm/L",
"              </option>",
"              <option value=\"1000|0|gm/dL\">",
"               gm/dL",
"              </option>",
"              <option value=\"1|0|mg%\">",
"               mg%",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mg/dL\">",
"               mg/dL",
"              </option>",
"              <option value=\"100|0|mg/mL\">",
"               mg/mL",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              INR",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"INR_param\" onblur=\"MELD_fx(); minMaxCheck();\" onchange=\"MELD_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\">",
"             &nbsp;",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Hemodialysis twice in week prior",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Hemodialysis_twice_in_week_prior_radio\" onclick=\"Creatinine_param.value = '4'; Creatinine = 4; MELD_fx();\" type=\"radio\" value=\"Yes\"/>",
"              Yes",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"3\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Hemodialysis_twice_in_week_prior_radio\" onclick=\"Creatinine_param.value = ''; MELD_Score_param.value = '';\" type=\"radio\" value=\"No\"/>",
"              No",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" valign=\"top\">",
"             <span class=\"medCalcFontOneBold\">",
"              Exception Diagnoses Age 12 to 17 Years",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input checked=\"checked\" name=\"Exception_Diagnoses_Age_12_to_17_Years_radio\" onclick=\"MELD_fx();\" type=\"radio\" value=\"Non contributory|0\"/>",
"              Non contributory (0)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Exception_Diagnoses_Age_12_to_17_Years_radio\" onclick=\"MELD_fx();\" type=\"radio\" value=\"Urea cycle disorder|1\"/>",
"              Urea cycle disorder (1)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Exception_Diagnoses_Age_12_to_17_Years_radio\" onclick=\"MELD_fx();\" type=\"radio\" value=\"Organic acidemia|1\"/>",
"              Organic acidemia (1)",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"left\">",
"             <br/>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             <span class=\"medCalcFontOne\">",
"              <input name=\"Exception_Diagnoses_Age_12_to_17_Years_radio\" onclick=\"MELD_fx();\" type=\"radio\" value=\"Hepatoblastoma|1\"/>",
"              Hepatoblastoma (1)",
"             </span>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              MELD Score",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"MELD_Score_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       The Model of End-stage Liver Disease, or",
"       <b>",
"        MELD Score",
"       </b>",
"       is used to estimate relative disease severity and likely survival of patients awaiting liver transplantation.",
"      </li>",
"      <li>",
"       Children under the age of 12 should be assessed by the",
"       <b>",
"        PELD Score",
"       </b>",
"       .",
"      </li>",
"      <li>",
"       If a patient has had 2 or more hemodialysis treatments or 24 hours of CVVHD in the week prior to the time of the scoring,",
"       <b>",
"        Creatinine",
"       </b>",
"       will be set to 4 mg/dL, the maximum creatinine level allowed in the model.",
"      </li>",
"      <li>",
"       If the patient is between 12 and 17 years old, and has either a urea cycle disorder, organic acidemia or hepatoblastoma, the",
"       <b>",
"        MELD Score",
"       </b>",
"       is set at 30.",
"      </li>",
"      <li>",
"       For patients with hepatocellular carcinoma, the PELD/MELD score is increased according to an algorithm established by UNOS (United Network for Organ Sharing.)",
"      </li>",
"      <li>",
"       Additional information about the",
"       <b>",
"        MELD",
"       </b>",
"       and",
"       <b>",
"        PELD",
"       </b>",
"       scores is at the UNOS website,  file://optn.transplant.hrsa.gov/resources/",
"       <wbr>",
"       </wbr>",
"       professionalResources.asp?index=8",
"      </li>",
"      <li>",
"       Please see appropriate UpToDate topic reviews for further information.",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOne\">",
"     Equation parameters such as",
"     <b>",
"      Exception Diagnoses Age 12 to 17 Years",
"     </b>",
"     have two or more discrete values that may be used in the calculation. The numbers in the parentheses, e.g.  (0), represent the values that will be used.",
"    </span>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21874=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function MELD_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.MELD_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Creatinine_param.value.indexOf(',') >= 0){ Creatinine_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Creatinine_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Creatinine_unit.options[Creatinine_unit.selectedIndex].value.split('|');",
"Creatinine = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Bilirubin_param.value.indexOf(',') >= 0){ Bilirubin_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Bilirubin_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Bilirubin_unit.options[Bilirubin_unit.selectedIndex].value.split('|');",
"Bilirubin = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (INR_param.value.indexOf(',') >= 0){ INR_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(INR_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"INR = param_value;",
"if (Exception_Diagnoses_Age_12_to_17_Years_radio[0].checked){ Exception_Diagnoses_Age_12_to_17_Years = 0; }",
"if (Exception_Diagnoses_Age_12_to_17_Years_radio[1].checked){ Exception_Diagnoses_Age_12_to_17_Years = 1; }",
"if (Exception_Diagnoses_Age_12_to_17_Years_radio[2].checked){ Exception_Diagnoses_Age_12_to_17_Years = 1; }",
"if (Exception_Diagnoses_Age_12_to_17_Years_radio[3].checked){ Exception_Diagnoses_Age_12_to_17_Years = 1; }",
"dp = 0;",
"if (Hemodialysis_twice_in_week_prior_radio[0].checked){",
"Creatinine_param.value = '4'; Creatinine = 4;",
"for(i = 0; i < Creatinine_unit.options.length; i++){",
"if (Creatinine_unit.options[i].value == '1|0|mg/dL') Creatinine_unit.selectedIndex = i;",
"}}",
"MELD_Score =  10 * ((0.957 * ln(Creatinine)) + (0.378 * ln(Bilirubin)) + (1.12 * ln(INR))) + 6.43;",
"",
"if (doCalc) MELD_Score_param.value = fixDP(MELD_Score, dp);",
"",
"",
"",
"if (Exception_Diagnoses_Age_12_to_17_Years && (Age >= 12) && (Age <= 17)){",
"alert('Beacuse of this specific disease, the MELD Score is set at 30');",
"MELD_Score_param.value = '30';",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MELD_form){",
"",
"if (Age_param.value && Age < 12) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 12 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Creatinine_param.value && Creatinine < 1) {",
"Creatinine = 0;",
"Creatinine_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Creatinine is 1 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Creatinine_param.value && Creatinine > 4) {",
"Creatinine_param.value = \"\";",
"clrResults();",
"Creatinine = 0;",
"doCalc = false;",
"alert(\"The maximum value for Creatinine is 4 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin < 1) {",
"Bilirubin = 0;",
"Bilirubin_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Bilirubin is 1 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Bilirubin_param.value && Bilirubin > 200) {",
"Bilirubin_param.value = \"\";",
"clrResults();",
"Bilirubin = 0;",
"doCalc = false;",
"alert(\"The maximum value for Bilirubin is 200 mg/dL.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR < 1) {",
"INR = 0;",
"INR_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for INR is 1 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (INR_param.value && INR > 100) {",
"INR_param.value = \"\";",
"clrResults();",
"INR = 0;",
"doCalc = false;",
"alert(\"The maximum value for INR is 100 .\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.MELD_form){",
"",
"MELD_Score_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f21_23_21874=null;
var title_f21_23_21875="Low voltage limb leads tutorial";
var content_f21_23_21875=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Low voltage in the limb leads",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 111px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low voltage of the limb leads is present when the amplitude of the QRS complex in each of the three standard limb leads (1, 2, and 3) is &lt;5 mm. Each large box represents 5 mm (calibration: 1 mV = 10 mm).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21875=[""].join("\n");
var outline_f21_23_21875=null;
var title_f21_23_21876="Psyllium: Patient drug information";
var content_f21_23_21876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Psyllium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=see_link\">",
"     see \"Psyllium: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/34/1573?source=see_link\">",
"     see \"Psyllium: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bulk-K [OTC];",
"     </li>",
"     <li>",
"      Fiberall&reg; [OTC];",
"     </li>",
"     <li>",
"      Fibro-Lax [OTC];",
"     </li>",
"     <li>",
"      Fibro-XL [OTC];",
"     </li>",
"     <li>",
"      Hydrocil&reg; Instant [OTC];",
"     </li>",
"     <li>",
"      Konsyl-D&trade; [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Easy Mix&trade; [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Orange [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; Original [OTC];",
"     </li>",
"     <li>",
"      Konsyl&reg; [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; Plus Calcium [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; Smooth Texture [OTC];",
"     </li>",
"     <li>",
"      Metamucil&reg; [OTC];",
"     </li>",
"     <li>",
"      Natural Fiber Therapy Smooth Texture [OTC];",
"     </li>",
"     <li>",
"      Natural Fiber Therapy [OTC];",
"     </li>",
"     <li>",
"      Reguloid [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Metamucil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691793",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat irritable bowel syndrome.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to raise fiber in the diet.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702826",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to psyllium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703776",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bowel block.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698108",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gas.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly cramps.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix powder with water and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11456 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21876=[""].join("\n");
var outline_f21_23_21876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215645\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215646\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018219\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018218\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018223\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018224\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018226\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018221\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018222\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018227\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018228\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/26/8614?source=related_link\">",
"      Psyllium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/34/1573?source=related_link\">",
"      Psyllium: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_23_21877="Indinavir crystals";
var content_f21_23_21877=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Photomicrographs showing urine sediment of a patient with indinavir sulfate crystalluria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 224px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light microscopic photographs of a fresh unstained preparation of urinary sediment showing three different forms of indinavir sulfate crystals.",
"    <br/>",
"    (A) Rectangular plates of various sizes containing needle-shaped crystals. The plates have irregular borders with occasional tapering, and internal layering evident in the largest forms (arrows). Small, triangular pieces (arrowheads) represent broken ends of needles.",
"    <br/>",
"    (B) A sheaf of densely packed indinavir sulfate needles.",
"    <br/>",
"    (C) Several indinavir crystal groupings are arranged in a rosette.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Gagnon RF, Tsoukas CM, Watters AK, Ann Intern Med 1998; 128:321.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21877=[""].join("\n");
var outline_f21_23_21877=null;
var title_f21_23_21878="Heat illness (other than heat stroke) in children";
var content_f21_23_21878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Heat illness (other than heat stroke) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21878/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21878/contributors\">",
"     Paul Ishimine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21878/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21878/contributors\">",
"     Daniel F Danzl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21878/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21878/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/23/21878/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat illness occurs along a spectrum of disease from minor syndromes (eg, miliaria, heat cramps) to life-threatening processes, such as heat stroke. While there are many manifestations of heat-related illnesses, all heat-related illnesses result from excessive heat exposure caused by an increased environmental heat burden, an inability of the body to dissipate endogenous heat, or a combination of these two factors.",
"   </p>",
"   <p>",
"    The manifestations, evaluation, and management of heat illness in children other than heat stroke will be reviewed here. Heat stroke in the pediatric patient and heat illness in the adult patient are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link\">",
"     \"Heat stroke in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body temperature is maintained within a narrow range by balancing heat load with heat dissipation. The body's heat load results from both metabolic processes and absorption of heat from the environment. Evaporation is the principal mechanism of heat loss in a hot environment, but this becomes ineffective above a relative humidity of 75 percent. The other major methods of heat dissipation &mdash; radiation (emission of infrared electromagnetic energy), conduction (direct transfer of heat to an adjacent, cooler object), and convection (direct transfer of heat to convective air currents) &mdash; cannot efficiently transfer heat when environmental temperature exceeds skin temperature (typically 35&ordm;C or 95&ordm;F).",
"   </p>",
"   <p>",
"    Children differ from adults with respect to their anatomical and physiologic response to heat stress. These differences translate into a potentially greater risk for severe heat illness in children, especially infants and young athletes. The pathophysiology of heat illness in children is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H4#H4\">",
"     \"Heat stroke in children\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION AND MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;All heat-related illnesses result from excessive heat exposure caused by an increased environmental heat burden, an inability of the body to dissipate endogenous heat, or a combination of these two factors. There are many manifestations of heat-related illnesses (",
"    <a class=\"graphic graphic_table graphicRef70997 \" href=\"UTD.htm?4/45/4829\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Miliaria (heat rash)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miliaria is a common finding in newborns, especially in warm climates. It may also occur in older individuals. Accumulation of sweat beneath eccrine sweat ducts results in obstruction by keratin at the level of the stratum corneum. Pruritus is common. Several types of lesions may result (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link&amp;anchor=H10#H10\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\", section on 'Miliaria'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Miliaria crystallina is characterized by small thin-walled vesicles resembling dewdrops without inflammation (",
"      <a class=\"graphic graphic_picture graphicRef55627 \" href=\"UTD.htm?33/38/34405\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Miliaria rubra (\"heat rash\", \"prickly heat\") occurs when the obstructed sweat leaks into the dermis and causes a localized inflammatory response, resulting in small groups of pruritic, erythematous papules and pustules (",
"      <a class=\"graphic graphic_picture graphicRef68376 \" href=\"UTD.htm?11/1/11284\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Miliaria pustulosa also results from localized inflammation; it consists of pustules with an erythematous base similar to miliaria rubra.",
"     </li>",
"     <li>",
"      Miliaria profunda is papular or papulopustular and skin colored.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This benign condition typically resolves without specific treatment when the individual is placed in a cooler environment with associated measures to reduce sweating, such as light, loose clothing, and cool baths.",
"   </p>",
"   <p>",
"    On occasion, nonspecific treatments may be used for pruritus (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/34/38433?source=see_link\">",
"     calamine lotion",
"    </a>",
"    , anhydrous lanolin, wet compresses, topical corticosteroids), and oral antihistamines (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/23/19830?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose). Superinfection of miliaria (eg, impetigo) rarely occurs and should be treated with antistaphylococcal antibiotics (eg, topical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"     mupirocin",
"    </a>",
"    or oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heat edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat edema is most commonly seen in unacclimatized elderly persons. This mild form of heat illness involves the hands and feet and is caused by vasodilation with pooling of interstitial fluid in dependent extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/2\">",
"     2",
"    </a>",
"    ]. Core body temperature remains normal.",
"   </p>",
"   <p>",
"    Management consists of moving to a cooler environment, elevation of the extremities, and use of compression stockings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/3\">",
"     3",
"    </a>",
"    ]. These patients do not have heart failure and diuretics should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Heat syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat syncope refers to dizziness, orthostatic hypotension, and syncope that occur in patients with heat-related peripheral vasodilation and venous pooling [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/2\">",
"     2",
"    </a>",
"    ]. Syncope often occurs in patients who remain standing after significant exertion or who rapidly change position during exertion. These patients have a normal core body temperature and a rapid return to normal mental status once they are supine.",
"   </p>",
"   <p>",
"    Treatment includes moving the patient to a cooler environment and administering intravenous normal saline (initial infusion 20",
"    <span class=\"nowrap\">",
"     mL/kg;",
"    </span>",
"    maximum initial dose 1 L) or providing oral rehydration with salt containing liquids until the patient no longer has orthostatic vital signs changes. While orthostatic the patient should maintain a supine position until volume repletion has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heat cramps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat cramps refer to painful muscular cramping that may occur during or after exertion in hot environments. The cramping commonly involves the large muscle groups of the legs (eg, quadriceps, gastrocnemius), abdomen, or arms. Patients may have a normal or elevated core body temperature. However, core body temperature does not exceed 40&ordm;C (104&ordm;F).",
"   </p>",
"   <p>",
"    The affected muscles often respond to passive stretching to \"work out\" the cramp. Reversal of fluid losses through oral rehydration with salt containing liquids may help prevent additional cramping [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Intravenous normal saline (initial infusion 20",
"    <span class=\"nowrap\">",
"     mL/kg;",
"    </span>",
"    maximum initial dose 1 L) is indicated if cramping persists despite muscle stretching, muscle massage, and oral rehydration.",
"   </p>",
"   <p>",
"    Heat cramps differ from heat tetany because they are not associated with circumoral paresthesias and do not typically cause upper extremity spasms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Heat tetany",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heat stress may cause hyperventilation that may cause respiratory alkalosis, positive Chvostek or Trousseau sign, laryngospasm, or spontaneous carpopedal spasm (heat tetany) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/1\">",
"     1",
"    </a>",
"    ]. Affected patients often complain of circumoral paresthesias. Core body temperature may be normal or elevated up to 40&ordm;C (104&ordm;F).",
"   </p>",
"   <p>",
"    Treatment consists of moving the patient to a cooler environment, which typically causes the hyperventilation to cease and the symptoms to abate. Consideration must be given to other serious etiologies, such as status asthmaticus, metabolic acidosis pain, central nervous system disorders, and drug intoxication, and these diagnoses must be excluded.",
"   </p>",
"   <p>",
"    Occasionally, additional measures may be necessary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In those patients with persistent hyperventilation and symptoms despite cooling, placement of a partial rebreather oxygen mask with oxygen flow set below 5 liters per minute allows the patient to rebreathe carbon dioxide without causing hypoxia and may assist in terminating the hyperventilation.",
"     </li>",
"     <li>",
"      Benzodiazepine administration in the form of oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"       diazepam",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      may be necessary to end the acute episode in patients who do not respond to cooling or to rebreathing of carbon dioxide.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Heat exhaustion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heat exhaustion have known heat exposure and an elevated core body temperature between 37&ordm;C (98.6&ordm;F) and 40&ordm;C (104&ordm;F). Additional symptoms include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Sweating (especially when associated with exercise)",
"     </li>",
"     <li>",
"      Nausea, vomiting",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Fatigue, weakness",
"     </li>",
"     <li>",
"      Dizziness",
"     </li>",
"     <li>",
"      Syncope with prompt return of normal mental status",
"     </li>",
"     <li>",
"      Severe thirst",
"     </li>",
"     <li>",
"      Normal mental status or mild confusion that responds rapidly (within 30 minutes) to cooling",
"     </li>",
"     <li>",
"      Signs of mild to moderate dehydration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some overlap of symptoms between heat exhaustion and heat stroke (",
"    <a class=\"graphic graphic_table graphicRef65625 \" href=\"UTD.htm?11/55/12156\">",
"     table 2",
"    </a>",
"    ). While the distinction between heat exhaustion and heat stroke is sometimes unclear, children with elevated body temperature and CNS abnormalities should be treated as victims of heat stroke, given the significant morbidity and mortality associated with this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H16#H16\">",
"     \"Heat stroke in children\", section on 'Hospital management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While most patients with heat exhaustion have normal electrolytes, some patients may have increased serum sodium due to hypotonic fluid losses, or decreased serum sodium due to excess salt losses in the sweat that may be exacerbated by hypotonic fluid replacement. Thus, these patients should receive salt-containing oral fluids (eg, flavored sports drinks such as Gatorade&reg; or intravenous normal saline).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Prehospital Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prompt recognition of heat exhaustion is important, because some cases progress to heat stroke. Unfortunately, many patients who develop heat stroke do not have antecedent heat exhaustion. Children with symptoms of heat exhaustion should stop exercising immediately and be moved to a cooler environment (eg, natural shade, air conditioned vehicle, air conditioned building). Excess clothing should be removed, and the patient should be given chilled salt-containing liquids (eg, flavored sports drinks such as Gatorade&reg;) to drink. Most patients with mild heat exhaustion respond to these measures and do not require further care [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hospital management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who do not respond to prehospital measures or who initially present with dehydration or mental status changes warrant hospital evaluation. In addition to maintaining a cool ambient environment, such patients should undergo the following care:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Measurement of rectal temperature",
"     </li>",
"     <li>",
"      Intravenous bolus of normal saline (20",
"      <span class=\"nowrap\">",
"       mL/kg;",
"      </span>",
"      maximum initial infusion 1 L)",
"     </li>",
"     <li>",
"      Measurement of serum electrolytes and treatment of any sodium abnormalities (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Therapy according to serum sodium'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children with mild confusion should have rapid clearing of their mental status within 30 minutes of initiation of treatment for heat exhaustion. Children with altered mental status on arrival to the hospital and a history of exertion in warm weather should be treated as patients with heat stroke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link\">",
"     \"Heat stroke in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with heat exhaustion who require hospital care recover fully within a few hours and can be discharged home. Rarely, patients with heat exhaustion may need to be admitted to the hospital for correction of significant electrolyte abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION OF HEAT ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful prevention of heat-related morbidity and mortality requires recognition of the potential for heat stress posed by environmental conditions and appropriate adaptation to elevated ambient temperature during outside activities occurs. Specific actions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Activity restriction",
"      </strong>",
"      &ndash; Clinicians should support efforts to curtail organized athletic activities and warn the public of danger when weather conditions pose a significant risk for heat injury. Up to 70 percent of the risk for heat illness is attributable to excess humidity, followed by elevated solar radiation (20 percent) and increased temperature (10 percent). Risk for heat stress can be identified using either the wet bulb globe temperature (WBGT) or the heat index [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. The WBGT takes into account all three weather factors when assessing environmental conditions. However, the heat index, which only takes into account humidity and temperature, is more easily obtainable (",
"      <a class=\"external\" href=\"file://www.nws.noaa.gov/om/heat/index.shtml\">",
"       www.nws.noaa.gov/om/heat/index.shtml",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Specific activity restrictions are suggested for given levels of heat index or WBGT (",
"      <a class=\"graphic graphic_table graphicRef53860 \" href=\"UTD.htm?10/21/10588\">",
"       table 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. Recommended adaptations include more hydration breaks, more frequent player substitutions during organized competition, ensuring a shaded area for rest, scheduling of practices or games earlier or later in the day when heat conditions abate, or canceling athletic activities when the risk of severe heat illness is too high. When activity is allowed, complete rest and a cool-down period after a period of strenuous exercise may reduce the risk of increased heat strain during a subsequent exercise period in some children [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/9\">",
"       9",
"      </a>",
"      ]. Children who are currently ill or recovering from an illness (especially fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gastrointestinal illnesses) should avoid or limit exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Maintenance of hydration",
"      </strong>",
"      &ndash; Scheduled hydration breaks with strong encouragement for drinking is very important in children because they are more likely to inadequately replenish fluid losses during prolonged exercise when dehydrated relative to adults [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/10\">",
"       10",
"      </a>",
"      ]. General guidelines suggest 100 to 250 mL (three to eight ounces) every 20 minutes for 9 to 12 year old children and up to 1 to 1.5 liter (34 to 50 ounces) per hour in adolescents assuming normal preactivity hydration [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/8\">",
"       8",
"      </a>",
"      ]. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H6#H6\">",
"       \"Heat stroke in children\", section on 'Pediatric considerations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Flavoring water by adding both carbohydrates and sodium chloride increases fluid intake by as much as 90 percent versus offering unflavored water [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/11-13\">",
"       11-13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The adequacy of hydration can be measured by comparing pre- and post-activity dry weight. One rule of thumb is to consume 240 mL (8 ounces) of fluid for every pound lost during the event [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/6\">",
"       6",
"      </a>",
"      ]. Athletes with persistent weight loss of 2 percent or more should be withheld from activity since unreplaced fluid losses over consecutive days of exercise markedly increase the risk for heat illness.",
"     </li>",
"     <li>",
"      <strong>",
"       Appropriate clothing",
"      </strong>",
"      &ndash; Children should wear a single layer of absorbent, loose fitting clothing to maximize convective heat loss. Light colors help reduce absorption of solar radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Acclimatization",
"      </strong>",
"      &ndash; Heat acclimation provides the best protection against heat exhaustion and heat stroke, but this takes repeated exposures to heat. The number and duration of exposures necessary for acclimatization varies by age. For example, an older adolescent may become acclimatized after four successive days of limited heat exposure. In contrast, a young school age child typically needs up to 14 days to achieve the same physiologic endpoint [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21878/abstract/6,7,14\">",
"       6,7,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=see_link&amp;anchor=H6#H6\">",
"       \"Heat stroke in children\", section on 'Pediatric considerations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37105?source=see_link\">",
"       \"Patient information: Heat stroke (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All heat-related illnesses result from excessive heat exposure caused by an increased environmental heat burden, an inability of the body to dissipate endogenous heat, or a combination of these two factors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations and treatment of minor heat illness, heat exhaustion, and heat stroke are summarized in the tables (",
"      <a class=\"graphic graphic_table graphicRef70997 \" href=\"UTD.htm?4/45/4829\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65625 \" href=\"UTD.htm?11/55/12156\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt recognition of heat exhaustion is important because some patients will progress to heat stroke. Patients who do not respond to prehospital measures or who initially present with dehydration or mental status changes warrant hospital evaluation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Heat exhaustion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ishimine P. Hyperthermia. In: Pediatric Emergency Medicine, Baren JM, Rothrock SG, Brennan JA, Brown L.  (Eds), Saunders Elsevier, Philadelphia 2008. p.992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/2\">",
"      Howe AS, Boden BP. Heat-related illness in athletes. Am J Sports Med 2007; 35:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/3\">",
"      DeFranco MJ, Baker CL 3rd, DaSilva JJ, et al. Environmental issues for team physicians. Am J Sports Med 2008; 36:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/4\">",
"      Lukins JL, Feldman MJ, Summers JA, Verbeek PR. A paramedic-staffed medical rehydration unit at a mass gathering. Prehosp Emerg Care 2004; 8:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/5\">",
"      Wetterhall SF, Coulombier DM, Herndon JM, et al. Medical care delivery at the 1996 Olympic Games. Centers for Disease Control and Prevention Olympics Surveillance Unit. JAMA 1998; 279:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/6\">",
"      Bytomski JR, Squire DL. Heat illness in children. Curr Sports Med Rep 2003; 2:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/7\">",
"      Jardine DS. Heat illness and heat stroke. Pediatr Rev 2007; 28:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/8\">",
"      Council on Sports Medicine and Fitness and Council on School Health, Bergeron MF, Devore C, et al. Policy statement&mdash;Climatic heat stress and exercising children and adolescents. Pediatrics 2011; 128:e741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/9\">",
"      Bergeron MF, Laird MD, Marinik EL, et al. Repeated-bout exercise in the heat in young athletes: physiological strain and perceptual responses. J Appl Physiol 2009; 106:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/10\">",
"      Bar-Or O, Dotan R, Inbar O, et al. Voluntary hypohydration in 10- to 12-year-old boys. J Appl Physiol 1980; 48:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/11\">",
"      Bar-Or O, Wilk B. Water and electrolyte replenishment in the exercising child. Int J Sport Nutr 1996; 6:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/12\">",
"      Wilk B, Bar-Or O. Effect of drink flavor and NaCL on voluntary drinking and hydration in boys exercising in the heat. J Appl Physiol 1996; 80:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/13\">",
"      Wilk B, Kriemler S, Keller H, Bar-Or O. Consistency in preventing voluntary dehydration in boys who drink a flavored carbohydrate-NaCl beverage during exercise in the heat. Int J Sport Nutr 1998; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21878/abstract/14\">",
"      Inbar O, Bar-Or O, Dotan R, Gutin B. Conditioning versus exercise in heat as methods for acclimatizing 8- to 10-yr-old boys to dry heat. J Appl Physiol 1981; 50:406.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6592 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-6DAE62D42F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21878=[""].join("\n");
var outline_f21_23_21878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Miliaria (heat rash)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heat edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Heat syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heat cramps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Heat tetany",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Heat exhaustion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Prehospital Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hospital management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION OF HEAT ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6592|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/38/34405\" title=\"picture 1\">",
"      Miliaria crystallina",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/1/11284\" title=\"picture 2\">",
"      Miliaria rubra",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6592|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/45/4829\" title=\"table 1\">",
"      Minor heat illness treatment in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/55/12156\" title=\"table 2\">",
"      Heat stroke versus heat exhaustion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/21/10588\" title=\"table 3\">",
"      Heat index and wet bulb globe temperature risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10234?source=related_link\">",
"      Heat stroke in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/15/37105?source=related_link\">",
"      Patient information: Heat stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_23_21879="Bronchial atresia CXR II";
var content_f21_23_21879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58630%7EPULM%2F60010%7EPULM%2F67715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58630%7EPULM%2F60010%7EPULM%2F67715&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left upper lobe bronchial atresia seen on a chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiograph demonstrates a tubular mass in the left hilar region with hyperexpansion and hyperlucency of the left upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left upper lobe bronchial atresia seen on an axial CT image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial CT scan with lung window settings shows marked hyperexpansion of the left upper lobe a tubular branching hilar mass and absence of the proximal left upper lobe bronchus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left upper lobe bronchial atresia seen on a coronal CT image",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal multiplanar reformat with mediastinal window settings shows the tubular hilar mass consistent with a mucoid impaction distal to the atretic bronchus. No evidence for an endobronchial tumor is seen, but tubular calcifications are seen in the mucoid impaction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21879=[""].join("\n");
var outline_f21_23_21879=null;
var title_f21_23_21880="Nodular basal cell carcinomas";
var content_f21_23_21880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61190%7EDERM%2F65704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61190%7EDERM%2F65704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A typical nodular basal cell carcinoma presents as a well-circumscribed nodule with a translucent or pearly appearance and telangiectasias (most evident in the left panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pearly papule with telangiectasias is representative of a nodular basal cell carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21880=[""].join("\n");
var outline_f21_23_21880=null;
var title_f21_23_21881="Diagnosis and treatment of pulmonary histoplasmosis";
var content_f21_23_21881=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of pulmonary histoplasmosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21881/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21881/contributors\">",
"     Joseph Wheat, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21881/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21881/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21881/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21881/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21881/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/23/21881/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histoplasmosis is a common endemic mycosis that is usually asymptomatic, but occasionally results in severe illness. Histoplasmosis and its causative agent, Histoplasma capsulatum, are found worldwide, but particularly in North and Central America. Within the United States, infection is most common in the midwestern states located in the Ohio and Mississippi River valleys. Among the endemic mycoses, it is the most common cause for hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis and treatment of the various histoplasmosis pulmonary syndromes will be reviewed here. The pathogenesis and clinical features of these syndromes and issues regarding histoplasmosis in HIV-infected patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1449?source=see_link\">",
"     \"Diagnosis and treatment of histoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHEN TO SUSPECT HISTOPLASMOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary histoplasmosis should be considered in patients with the following clinical presentations, particularly in the appropriate epidemiologic setting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pneumonia with mediastinal or hilar lymphadenopathy",
"     </li>",
"     <li>",
"      Mediastinal or hilar masses",
"     </li>",
"     <li>",
"      Pulmonary nodule",
"     </li>",
"     <li>",
"      Cavitary lung disease",
"     </li>",
"     <li>",
"      Pericarditis with mediastinal lymphadenopathy",
"     </li>",
"     <li>",
"      Pulmonary manifestations with arthritis or arthralgia plus erythema nodosum",
"     </li>",
"     <li>",
"      Dysphagia caused by esophageal narrowing",
"     </li>",
"     <li>",
"      Superior vena cava syndrome or obstruction of other mediastinal structures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These manifestations place pulmonary histoplasmosis in the differential diagnosis of sarcoidosis, tuberculosis, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/2\">",
"     2",
"    </a>",
"    ]. Failure to exclude histoplasmosis in the evaluation of sarcoidosis may lead to marked disease exacerbation if immunosuppressive therapy is initiated in a patient who actually has acute histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/3\">",
"     3",
"    </a>",
"    ]. Similarly, failure to consider histoplasmosis in patients under evaluation for malignancy may lead to unnecessary surgical evaluation. Thus, in the appropriate epidemiologic setting, testing for histoplasmosis should be included for patients who are under evaluation for these conditions. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Distinction from sarcoidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathology using stains for fungi, cultures, antigen detection, and serologic tests for Histoplasma-specific antibodies can all help one make the diagnosis of pulmonary histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/4\">",
"     4",
"    </a>",
"    ]. The characteristics of these tests vary in the different histoplasmosis syndromes, but all can serve as the basis for diagnosis in patients with compatible clinical findings. Each test has certain limitations that must be recognized if it is to be used correctly. The materials for histoplasmin skin testing are no longer available.",
"   </p>",
"   <p>",
"    A general description of the various diagnostic methods for histoplasmosis follows. Decision-making regarding the use of individual assays within the context of varying clinical presentations is discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Selection of diagnostic tests for different pulmonary syndromes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histopathology and cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphologic findings in biopsy specimens include granulomas (in most cases), lymphohistiocytic aggregates, and diffuse mononuclear cell infiltrates (",
"    <a class=\"graphic graphic_picture graphicRef74406 \" href=\"UTD.htm?5/36/5699\">",
"     picture 1",
"    </a>",
"    ). Histopathologic examination of lung or mediastinal lymph node tissue using special stains that highlight fungi permits rapid diagnosis of histoplasmosis (",
"    <a class=\"graphic graphic_picture graphicRef65482 \" href=\"UTD.htm?42/55/43888\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/5\">",
"     5",
"    </a>",
"    ]. The sensitivity and specificity is decreased if pathologists are inexperienced in the recognition of H. capsulatum.",
"   </p>",
"   <p>",
"    Yeast-phase organisms of H. capsulatum are ovoid in shape, measure 2 to 4 micron in diameter, and demonstrate narrow-based budding. Care must be taken in interpretation of fungal stains because Candida glabrata, Cryptococcus neoformans, Pneumocystis jirovecii, and staining artifacts may be misidentified as H. capsulatum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fungal cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cultures are most useful in patients with chronic pulmonary histoplasmosis. Submission of multiple sputum or bronchoalveolar lavage cultures produces a positive yield in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, the sensitivity of respiratory cultures is much lower in localized disease or acute disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the low sensitivity of culture, the organism may not grow in culture for as long as six weeks; this delay in diagnosis may compromise care in a patient who is severely ill.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antigen detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of antigen using the Histoplasma antigen detection enzyme immunoassay (EIA) in the urine, blood or bronchoalveolar lavage fluid of infected patients provides rapid diagnostic information and is particularly useful in patients who are severely ill [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies have been performed using a commercial test that is currently available in the United States. In these studies, an H. capsulatum galactomannan can be detected in 60 to 83 percent of patients with acute pulmonary histoplasmosis, depending on the extent of the lung involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. &nbsp;The highest sensitivity is obtained by testing both urine and serum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/9\">",
"     9",
"    </a>",
"    ]. Other tests have been developed using different antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study evaluated the utility of the Histoplasma antigen EIA on bronchoalveolar lavage fluid in the diagnosis of patients with pulmonary histoplasmosis, most of whom were immunocompromised and had diffuse disease; 29 of 31 patients with pulmonary histoplasmosis (94 percent) had positive antigen testing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cross-reactions can be seen in patients with blastomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/4\">",
"     4",
"    </a>",
"    ], coccidioidomycosis, penicilliosis (due to Penicillium marneffei), paracoccidioidomycosis, and African histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/13\">",
"     13",
"    </a>",
"    ], and also rarely in aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/5\">",
"     5",
"    </a>",
"    ], but not in patients infected with Candida or Cryptococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <strong>",
"     Please note that one of the authors (JW) is owner and Director of MiraVista Diagnostics, one of several companies that performs the Histoplasma antigen EIA.",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing is useful in the diagnosis of histoplasmosis in the patient with a compatible clinical presentation and epidemiologic risk factors (",
"    <a class=\"graphic graphic_figure graphicRef56766 \" href=\"UTD.htm?20/34/21038\">",
"     figure 1",
"    </a>",
"    ). Less than 1 percent of residents in endemic areas are seropositive by the immunodiffusion test and less than five percent have positive complement fixation assays; thus, background seropositivity is not a major limitation to serologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/14\">",
"     14",
"    </a>",
"    ]. It should be noted that antibody assays may be falsely negative in immunosuppressed patients. In acute cases, antibodies usually appear during the second month after exposure, and may thus be negative when first measured. Antibodies can remain positive for several years, and thus may not indicate disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Comparison of serologic methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement fixation test using antigens from the yeast and mycelial forms of H. capsulatum is slightly more sensitive than the immunodiffusion test. As an example, serologic study of 276 patients during an urban outbreak of histoplasmosis found that complement fixation had a sensitivity of almost 95 percent versus 90 percent with immunodiffusion testing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/14\">",
"     14",
"    </a>",
"    ]. Complement fixation titers of 1:32 or higher are highly suggestive of acute infection, but titers of 1:8 or 1:16 should not be disregarded because titers in this range occur in about one-third of cases with active disease.",
"   </p>",
"   <p>",
"    However, the immunodiffusion test has greater specificity than the complement fixation test. Positive results with the complement fixation test may represent a persistent antibody response from a previous episode of histoplasmosis or infection with other fungi (eg, coccidioidomycosis, blastomycosis). Positive results may also occur in patients with other granulomatous diseases (eg, sarcoidosis, tuberculosis); the cause of this is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/15\">",
"     15",
"    </a>",
"    ]. Of note is that active histoplasmosis should be excluded before making a diagnosis of sarcoidosis, and should be considered in patients presumed to have tuberculosis in which mycobacterial cultures and stains are negative. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Distinction from sarcoidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the immunodiffusion test, results are reported as M or H precipitins or bands. Most patients will develop an M band; the H precipitin band is detectable in fewer than 20 percent of cases. The H band is seen most often in patients who have disseminated infection, chronic cavitary pulmonary histoplasmosis, or more severe acute pulmonary histoplasmosis and is helpful for diagnosis when present. The M band becomes positive sooner than the H band and persists longer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some laboratories use an enzyme immunoassay as a screening serology for histoplasmosis. The enzyme immunoassay methods, however, have not been shown to be as sensitive as the complement fixation test, and may be falsely negative in patients with histoplasmosis. Furthermore, background seropositivity and cross reactivity in other endemic mycoses may be higher using enzyme immunoassay methods.",
"   </p>",
"   <p>",
"    In summary, positive serologic assays must be interpreted with caution in individuals who do not have clinical features that are suggestive of histoplasmosis. If the history is equivocal, documentation of infection with H. capsulatum by staining, culture, or antigen detection is highly desirable. On the other hand, serologic tests are often negative in immunosuppressed patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352373898\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of polymerase chain reaction (PCR) for diagnosis of histoplasmosis is uncertain. In one study, two of six culture-positive bronchoalveolar lavage (BAL) fluid specimens and nine of nine other respiratory or tissue specimens were positive using a PCR assay developed in a commercial laboratory, but comparison to microscopy was not reported, leaving open the question of whether PCR improves the sensitivity for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/17\">",
"     17",
"    </a>",
"    ]. In another report, PCR was positive only if organisms were seen by microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/18\">",
"     18",
"    </a>",
"    ]. Other studies noted a sensitivity of 8 percent of urine and 22 percent of BAL specimens that were positive for Histoplasma antigen, whereas results in cerebrospinal fluid (CSF) and serum were uniformly negative [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/8,19\">",
"     8,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Distinction from sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and radiographic findings in pulmonary histoplasmosis and sarcoidosis may be similar. A mistake in diagnosis can be disastrous if the patient is treated with corticosteroids or other immunosuppressive medications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/3\">",
"     3",
"    </a>",
"    ]. Although such patients may appear to improve transiently, they eventually experience progressive disseminated disease, which may result in increased morbidity and mortality if the true diagnosis is not identified. If there is a high suspicion for histoplasmosis (eg, a patient who has resided in an endemic area with clinical features that are suggestive of histoplasmosis), a tissue diagnosis should be pursued before initiating glucocorticoids, especially if the Histoplasma antigen test on urine and serum is negative. If initial antibody tests are negative, repeat testing is recommended before initiating glucocorticoid treatment, since seroconversion may occur. Antigen testing should be repeated following initiation of glucocorticoid therapy because progressive dissemination may occur if the patient has histoplasmosis rather than sarcoidosis. If bronchoscopy is performed, bronchoalveolar fluid also should be tested for antigen. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Antigen detection'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=see_link\">",
"     \"Treatment of pulmonary sarcoidosis with glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, histoplasmosis must be excluded before treating patients with presumed sarcoidosis with immunosuppressive medications, particularly in endemic areas. The evaluation should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antigen testing of urine, serum, and bronchoalveolar lavage fluid",
"     </li>",
"     <li>",
"      Fungal culture of bronchoalveolar lavage fluid, or other respiratory secretions",
"     </li>",
"     <li>",
"      Cytology or histopathology of respiratory specimens or lung tissue examined by an experienced pathologist",
"     </li>",
"     <li>",
"      Antibody testing of serum by immunodiffusion and complement fixation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive results suggesting active histoplasmosis would preclude immunosuppressive therapy, but negative results would not entirely exclude histoplasmosis. In such patients, the response to immunosuppressive therapy must be carefully monitored, including repeat antigen testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SELECTION OF DIAGNOSTIC TESTS FOR DIFFERENT PULMONARY SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The yield of the diagnostic modalities differs depending upon the extent of the infection and timing following exposure. A battery of tests is required to achieve the highest sensitivity for diagnosis. Antigen tests and serology may be negative when first performed, but become positive later as the illness progresses. Thus, follow-up testing is encouraged in a patient with progressive illness if the first tests are negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute diffuse pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fungal burden is often high in patients with diffuse infiltrates presenting within a month following exposure to a high inoculum of conidia. In such cases, antigen and antibody testing provide the highest sensitivity. Antibodies may be negative initially but positive a month later.",
"   </p>",
"   <p>",
"    Bronchoscopy or lung biopsy may be needed to establish the diagnosis in some cases when less invasive testing is not diagnostic or the illness is too severe to wait for results of antigen or antibody test. In such cases, pathology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    culture are positive in about 40 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Acute localized pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fungal burden is generally lower in patients presenting with symptoms of more than one month in duration accompanied by localized pulmonary infiltrates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal lymphadenopathy, and usually without a recognized exposure. Antigen may be detected in the urine or serum in only 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/4\">",
"     4",
"    </a>",
"    ]. Cultures and pathology of respiratory specimens or lung may be positive in some cases. Antigen testing of bronchoalveolar lavage fluid may improve the sensitivity over culture alone [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/5\">",
"     5",
"    </a>",
"    ]. Serological tests for antibodies are positive in over 90 percent of cases if both the immunodiffusion and complement fixation tests are performed",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Chronic cavitary pulmonary histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serology is positive in most cases, and the complement fixation titers are often high. Most patients are able to expectorate sputum, but some may require bronchoscopy to obtain adequate specimens. If sputum cannot be obtained, cultures are negative, complement fixation titers are low (1:8 or 1:16), or if another diagnosis is suspected (eg, lung cancer or mycobacterial infection), bronchoscopy should be performed. Cultures of sputum or bronchoscopy specimens have been reported to be positive in 65 to 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/20\">",
"     20",
"    </a>",
"    ]. Antigen was detected in the urine in seven of eight of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/4\">",
"     4",
"    </a>",
"    ] and in bronchoscopy specimens in five other patients who had negative antigen results in urine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lung biopsy is rarely needed and should be avoided in this population with obstructive lung disease because of the risk for surgical complications, including pneumothorax and bronchopleural fistula, as well as bacterial superinfection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mediastinal syndromes, broncholithiasis, and lung nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few, if any viable organisms persist in the tissues of patients with these manifestations of histoplasmosis, which represent complications of or expected sequelae of the healing process [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, cultures and antigen tests are usually negative, even though stains for fungi on the tissues may show organisms consistent with H. capsulatum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/21\">",
"     21",
"    </a>",
"    ]. In a review of fibrosing mediastinitis, evidence for prior infection with H. capsulatum was obtained by positive antibody tests in 17 of 58 (29 percent) patients who had these assays performed, and organisms compatible with H. capsulatum were seen in 11 of 43 (26 percent) biopsy specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/22\">",
"     22",
"    </a>",
"    ]. Tests for antigen are expected to be negative in most cases. &nbsp;",
"   </p>",
"   <p>",
"    Organisms can often be seen in pulmonary nodules, but cultures and test for antigens are negative, and antibodies may be detected in low titers of 1:8 or 1:16 by complement fixation in some cases.",
"   </p>",
"   <p>",
"    The main indication for surgery in these situations is to exclude malignancy in patients with non-calcified pulmonary nodules or mediastinal lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/23\">",
"     23",
"    </a>",
"    ]. In patients without risk factors for malignancy, follow up with computed tomography (CT) scan at three to six month intervals for one to two years is a reasonable approach. Surgery should rarely be required for diagnosis of fibrosing mediastinitis because the clinical syndrome is unique, and surgery may cause serious and avoidable complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=see_link\">",
"     \"Fibrosing mediastinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANTIFUNGAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical practice guidelines for the management of patients with histoplasmosis were updated in 2007 by the Infectious Diseases Society of America [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. (",
"    <a class=\"external\" href=\"file://www.journals.uchicago.edu/doi/abs/10.1086/521259\">",
"     www.journals.uchicago.edu/doi/abs/10.1086/521259",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for histoplasmosis varies according to the patient's clinical syndrome (",
"    <a class=\"graphic graphic_table graphicRef69894 \" href=\"UTD.htm?29/58/30636\">",
"     table 1",
"    </a>",
"    ). Most infections caused by H. capsulatum are self-limited and require no therapy. However, patients who are exposed to a large inoculum of Histoplasma and those who are immunocompromised usually require antifungal therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    all have in vitro activity against H. capsulatum, but clinical trials have only been conducted with itraconazole, fluconazole, and amphotericin B. Itraconazole is generally preferred for mild to moderate histoplasmosis, and amphotericin B has a role in the treatment of moderately severe and severe infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Amphotericin B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its potential toxicity,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    is reserved for the initial treatment of patients who have moderately severe or severe infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=see_link\">",
"     \"Amphotericin B nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lipid preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    are generally preferred because of reduced nephrotoxicity associated with their use. In addition, a more rapid response to treatment and improved survival have been noted with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    (AmBisome) when compared with amphotericin B deoxycholate in patients who have AIDS and disseminated histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the use of amphotericin B deoxycholate may be considered in patients without risk factors for renal insufficiency due to its lower cost [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dosing of the various",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    preparations is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       Liposomal amphotericin B",
"      </a>",
"      (AmBisome&reg;) (3",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      intravenously)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       Amphotericin B lipid complex",
"      </a>",
"      (Abelcet&reg;) (5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      intravenously)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      deoxycholate (0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      intravenously)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients often respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    within a few days and then can be switched to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    to finish the course of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=see_link\">",
"     \"Pharmacology of amphotericin B\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Itraconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    is highly active against H. capsulatum. In a Mycoses Study Group trial of patients with pulmonary histoplasmosis, cure was achieved in 81 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    is appropriate for patients not requiring hospitalization and for continuation of outpatient therapy in those initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . Itraconazole should be administered as a loading dose (200 mg orally three times daily for three days) in order to rapidly achieve therapeutic serum concentrations followed by 200 mg once or twice daily, depending upon the serum drug concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug levels should be measured after two weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. The dose should be adjusted to achieve a serum concentration of at least 3",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    as measured by bioassay, and at least 1",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    by high-performance liquid chromatography (HPLC). When HPLC is used in the assessment of drug levels, the sum of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    fraction and the hydroxy metabolite should be considered. The timing of the specimen following the dose is not critical because of itraconazole's long half-life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H27#H27\">",
"     \"Pharmacology of azoles\", section on 'Itraconazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The factors that affect",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    pharmacokinetics, including drug interactions, absorption, and drug formulation, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H31#H31\">",
"     \"Pharmacology of azoles\", section on 'Drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is well tolerated, and is available in both oral and intravenous preparations. However, fluconazole is not as active against H. capsulatum in vitro, and has produced less favorable results than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/27\">",
"     27",
"    </a>",
"    ]. In a Mycoses Study Group trial, fluconazole led to clinical improvement in only 54 percent of cases of pulmonary histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/27\">",
"     27",
"    </a>",
"    ]. Furthermore, the development of resistance to fluconazole has been reported in AIDS patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    is",
"    <strong>",
"     not",
"    </strong>",
"    recommended as a standard treatment for histoplasmosis and should only be used in patients who cannot tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    , or who cannot achieve adequate blood levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients who are treated with fluconazole for histoplasmosis should be monitored carefully for relapse. The recommended dosage is 400 to 800 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. capsulatum is highly susceptible in vitro to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/60/33737?source=see_link\">",
"     posaconazole",
"    </a>",
"    and has been used successfully as salvage therapy in patients who had failed other regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is active in vitro against H. capsulatum, and has been shown to be effective in a small number of patients with histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;H. capsulatum does not appear to be susceptible to the echinocandins in vitro and they have been ineffective in a murine model [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     THERAPY FOR PULMONARY HISTOPLASMOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical practice guidelines for the management of patients with histoplasmosis were updated in 2007 by the Infectious Diseases Society of America (IDSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. The therapeutic approach to pulmonary histoplasmosis varies according to the specific disease process (",
"    <a class=\"graphic graphic_table graphicRef69894 \" href=\"UTD.htm?29/58/30636\">",
"     table 1",
"    </a>",
"    ). (",
"    <a class=\"external\" href=\"file://www.journals.uchicago.edu/doi/abs/10.1086/521259\">",
"     www.journals.uchicago.edu/doi/abs/10.1086/521259",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Acute diffuse pulmonary histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is indicated in most patients with diffuse pulmonary infiltrates who present within a month of exposure to a large inoculum of H. capsulatum, and in all patients who have moderately severe or severe disease. Patients with dyspnea and hypoxemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    development of acute respiratory distress syndrome (ARDS) should be treated initially with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    . The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg/d",
"    </span>",
"    intravenously) for 1 to 2 weeks has been used in some patients with clinical benefit and is recommended in the IDSA guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. Amphotericin B should be dosed as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       Liposomal amphotericin B",
"      </a>",
"      (AmBisome&reg;) &mdash; 3",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/27/18871?source=see_link\">",
"       Amphotericin B lipid complex",
"      </a>",
"      (Abelcet&reg;) &mdash; 5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      intravenously",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      deoxycholate &mdash; 0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      intravenously",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Amphotericin B'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Clinical improvement is often dramatic and may occur within several days of therapy, permitting rapid transition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    to complete a twelve week course of therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     Itraconazole",
"    </a>",
"    can be used as initial therapy in patients who are not sufficiently ill to require hospitalization (ie, mild to moderate pulmonary histoplasmosis) but who have persistent symptoms for &gt;1 month [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. Itraconazole should be given as a loading dose (200 mg orally three times daily for the first three days), followed by a maintenance dose (200 mg orally once or twice daily) for six to twelve weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. Antifungal therapy can be discontinued when pulmonary infiltrates have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H253380950\">",
"    <span class=\"h2\">",
"     Acute localized pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy should be considered in symptomatic patients who present with localized infiltrates",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mediastinal lymphadenopathy and show no improvement after four weeks of symptoms. Whether therapy alters the course in such cases is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Chronic cavitary pulmonary histoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment is indicated in all patients with chronic pulmonary histoplasmosis because the infection results in progressive loss of pulmonary function in most patients and death in as many as 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    can halt disease progression and significantly reduces mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/32\">",
"     32",
"    </a>",
"    ]. Subsequent studies have shown the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/26\">",
"     26",
"    </a>",
"    ]. Itraconazole should be given as a loading dose (200 mg orally three times daily for the first three days), followed by a maintenance dose (200 mg orally once or twice daily) for at least one year. Some experts prefer 18 to 24 months of antifungal therapy given the substantial risk of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic abnormalities improve during the first year of treatment in at least two-thirds of cases, but often do not resolve completely. Treatment should not be discontinued until radiographic improvement has ceased.",
"   </p>",
"   <p>",
"    Serum and urine Histoplasma antigen tests are often negative in patients with chronic pulmonary histoplasmosis. Antibody titers should not be used to gauge the response to therapy, because antibodies to H. capsulatum may persist despite clinical improvement.",
"   </p>",
"   <p>",
"    Vigilance for relapse must be maintained after treatment is stopped, because as many as 10 to 20 percent of patients with chronic pulmonary histoplasmosis may experience a relapse. While most relapses occur within two years of stopping therapy, follow-up should be continued for at least five years. Chest radiographs should be obtained every six months for the first year after treatment is discontinued and then annually or with the recurrence of symptoms to exclude reactivation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Granulomatous mediastinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of untreated granulomatous mediastinitis is unpredictable, and its response to treatment has been difficult to assess objectively. Treatment is not indicated in asymptomatic patients in whom the findings may resolve without treatment. For symptomatic patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"     itraconazole",
"    </a>",
"    (200 mg orally three times daily for three days, followed by 200 mg orally once or twice daily) for 6 to 12 weeks is recommended, although there are no controlled trials to prove its efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical resection of obstructive masses can be considered and is generally safe for patients whose symptoms do not improve after one to three months of antifungal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/21\">",
"     21",
"    </a>",
"    ]. Of 27 cases undergoing resection of mediastinal nodes, lobectomy, or esophageal repair, only one experienced a complication [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/33\">",
"     33",
"    </a>",
"    ]. Excision is not indicated to prevent subsequent fibrosing mediastinitis because these two disease processes are not related [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Fibrosing mediastinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosing mediastinitis is a rare progressive fibrotic condition, which causes significant disability and death is some patients who have bilateral involvement, but can be milder and less disabling in those who have unilateral disease. Newer studies show better outcomes than older ones [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/22\">",
"     22",
"    </a>",
"    ]. The approach to therapy is described in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/21,23,24,34\">",
"     21,23,24,34",
"    </a>",
"    ] and will be briefly reviewed here (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=see_link\">",
"     \"Fibrosing mediastinitis\"",
"    </a>",
"    ) Large prospective studies with long-term follow-up have not been conducted, and predicting outcome in individual cases is difficult. Most authorities believe that neither antifungal nor anti-inflammatory treatment improves the outcome of this complication of histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/21,23,24,34\">",
"     21,23,24,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with symptoms of obstruction of pulmonary arteries or veins, stent placement has been used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In one study in which stenting was evaluated, major complications requiring immediate surgery occurred in 10 percent of cases, and one patient died following pulmonary vein angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/36\">",
"     36",
"    </a>",
"    ]. Placement of stents in the airways is discouraged for patients with histoplasmosis, since granulation tissue often invades the stent causing further obstruction of the airways, and airway stents may be difficult to remove should obstruction develop.",
"   </p>",
"   <p>",
"    Surgery should be discouraged because of high operative mortality rates and limited benefit. As an example, one review of 71 patients with fibrosing mediastinitis who had occlusion of the major central airways or major vessels found that only 40 percent benefited and 20 percent died as a result of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/21\">",
"     21",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Referral of patients with this condition to clinicians who are experienced with its management should be strongly encouraged in view of the poor prognosis and uncertainty of current treatment recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Broncholithiasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcified lymph nodes (broncholiths) rarely erode into adjacent bronchi, which can cause symptoms of hemoptysis and expectoration of tiny calcified particles. Lobectomy or transbronchial removal for relief of obstruction was effective in 13 cases, but complications of air leak and empyema occurred in one patient each [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/33\">",
"     33",
"    </a>",
"    ]. Antifungal therapy is not indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathogenesis and clinical features of pulmonary histoplasmosis\", section on 'Broncholithiasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Pulmonary nodules (histoplasmomas)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sites of healed Histoplasma lung infection can evolve into pulmonary nodules that can persist long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24,37\">",
"     24,37",
"    </a>",
"    ]. They are typically asymptomatic and may be identified incidentally on chest x-rays or computed tomography (CT) imaging. In the setting of one or a few isolated nodules, there is no evidence that antifungal therapy is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. However, symptomatic patients who have multiple or diffuse nodules require treatment as recommended for acute pulmonary histoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Acute diffuse pulmonary histoplasmosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     EXTRAPULMONARY MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Pericarditis or rheumatologic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericarditis and rheumatologic manifestations are caused by the inflammatory response to H. capsulatum rather than infection, per se. However, patients may or may not exhibit pulmonary manifestations. Symptomatic patients recover with antiinflammatory drugs alone. In two large series of 45 patients with pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/38,39\">",
"     38,39",
"    </a>",
"    ] and 24 patients with arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21881/abstract/40\">",
"     40",
"    </a>",
"    ], 67 of 69 patients recovered with antiinflammatory treatment alone, while two patients recovered following combination therapy with an antiinflammatory agent and an antifungal agent. We typically use a nonsteroidal anti-inflammatory drug;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is reserved for patients who fail to respond to nonsteroidal agents. Patients who have pericardial effusions causing hemodynamic compromise must have drainage of the pericardial fluid.",
"   </p>",
"   <p>",
"    Rare cases of disseminated histoplasmosis with involvement of the pericardium or joints must not be confused with these inflammatory syndromes; aggressive antifungal therapy is required in patients with disseminated disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=see_link\">",
"     \"Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/5/13393?source=see_link\">",
"       \"Patient information: Histoplasmosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Histoplasmosis is a common endemic mycosis that is usually asymptomatic, but occasionally results in severe illness. Histoplasmosis and its causative agent, Histoplasma capsulatum, are found worldwide, but particularly in North and Central America. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary histoplasmosis should be considered in patients with the following clinical presentations, particularly in the appropriate epidemiologic setting:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pneumonia with mediastinal or hilar lymphadenopathy",
"     </li>",
"     <li>",
"      Mediastinal or hilar masses",
"     </li>",
"     <li>",
"      Pulmonary nodule",
"     </li>",
"     <li>",
"      Cavitary lung disease",
"     </li>",
"     <li>",
"      Pericarditis with mediastinal lymphadenopathy",
"     </li>",
"     <li>",
"      Pulmonary manifestations with arthritis or arthralgia plus erythema nodosum",
"     </li>",
"     <li>",
"      Dysphagia caused by esophageal narrowing",
"     </li>",
"     <li>",
"      Superior vena cava syndrome or obstruction of other mediastinal structures. These manifestations place pulmonary histoplasmosis in the differential diagnosis of sarcoidosis, tuberculosis, and malignancy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'When to suspect histoplasmosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Histopathology using stains for fungi, cultures, antigen detection, and serologic tests for Histoplasma-specific antibodies all can help make a diagnosis of pulmonary histoplasmosis. &nbsp;(See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical and radiographic findings in pulmonary histoplasmosis and sarcoidosis may be similar. A mistake in diagnosis can be disastrous if the patient is treated with corticosteroids or other immunosuppressive medications. As a result, histoplasmosis must be excluded before treating patients with presumed sarcoidosis with immunosuppressive medications. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Distinction from sarcoidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The yield of the diagnostic modalities differs depending upon the extent of the infection and timing following exposure. A battery of tests is required to achieve the highest sensitivity for diagnosis. Antigen tests and serology may be negative when first performed, but become positive later as the illness progresses. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Selection of diagnostic tests for different pulmonary syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal treatment for histoplasmosis varies according to the patient's clinical syndrome (",
"      <a class=\"graphic graphic_table graphicRef69894 \" href=\"UTD.htm?29/58/30636\">",
"       table 1",
"      </a>",
"      ). Most infections caused by H. capsulatum are self-limited and require no therapy. However, patients who are exposed to a large inoculum of Histoplasma and those who are immunocompromised usually require antifungal therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"       Itraconazole",
"      </a>",
"      is generally preferred for mild to moderate histoplasmosis, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      for the treatment of moderately severe to severe infections. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy should be considered in patients with more than four weeks of symptoms, but may not be indicated in those with mild symptoms who are already improving. Therapy is indicated without delay in patients with moderately severe or severe disease. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Acute diffuse pulmonary histoplasmosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is indicated in all patients with chronic pulmonary histoplasmosis because the infection results in progressive loss of pulmonary function in most patients and death in as many as 30 percent of cases. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Chronic cavitary pulmonary histoplasmosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/1\">",
"      Chu JH, Feudtner C, Heydon K, et al. Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis 2006; 42:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/2\">",
"      Wheat LJ, Conces D, Allen SD, et al. Pulmonary histoplasmosis syndromes: recognition, diagnosis, and management. Semin Respir Crit Care Med 2004; 25:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/3\">",
"      Gulati M, Saint S, Tierney LM Jr. Clinical problem-solving. Impatient inpatient care. N Engl J Med 2000; 342:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/4\">",
"      Hage CA, Ribes JA, Wengenack NL, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis 2011; 53:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/5\">",
"      Hage CA, Davis TE, Fuller D, et al. Diagnosis of histoplasmosis by antigen detection in BAL fluid. Chest 2010; 137:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/6\">",
"      Wheat LJ, Wass J, Norton J, et al. Cavitary histoplasmosis occurring during two large urban outbreaks. Analysis of clinical, epidemiologic, roentgenographic, and laboratory features. Medicine (Baltimore) 1984; 63:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/7\">",
"      Wheat LJ. Approach to the diagnosis of the endemic mycoses. Clin Chest Med 2009; 30:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/8\">",
"      Wheat LJ. Improvements in diagnosis of histoplasmosis. Expert Opin Biol Ther 2006; 6:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/9\">",
"      Swartzentruber S, Rhodes L, Kurkjian K, et al. Diagnosis of acute pulmonary histoplasmosis by antigen detection. Clin Infect Dis 2009; 49:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/10\">",
"      Lindsley MD, Holland HL, Bragg SL, et al. Production and evaluation of reagents for detection of Histoplasma capsulatum antigenuria by enzyme immunoassay. Clin Vaccine Immunol 2007; 14:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/11\">",
"      Scheel CM, Samayoa B, Herrera A, et al. Development and evaluation of an enzyme-linked immunosorbent assay to detect Histoplasma capsulatum antigenuria in immunocompromised patients. Clin Vaccine Immunol 2009; 16:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/12\">",
"      Cloud JL, Bauman SK, Neary BP, et al. Performance characteristics of a polyclonal enzyme immunoassay for the quantitation of Histoplasma antigen in human urine samples. Am J Clin Pathol 2007; 128:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/13\">",
"      Wheat J, Wheat H, Connolly P, et al. Cross-reactivity in Histoplasma capsulatum variety capsulatum antigen assays of urine samples from patients with endemic mycoses. Clin Infect Dis 1997; 24:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/14\">",
"      Wheat J, French ML, Kohler RB, et al. The diagnostic laboratory tests for histoplasmosis: analysis of experience in a large urban outbreak. Ann Intern Med 1982; 97:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/15\">",
"      Wheat LJ, French ML, Wass JL. Sarcoidlike manifestations of histoplasmosis. Arch Intern Med 1989; 149:2421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/16\">",
"      Picardi JL, Kauffman CA, Schwarz J, Phair JP. Detection of precipitating antibodies to Histoplasma capsulatum by counterimmunoelectrophoresis. Am Rev Respir Dis 1976; 114:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/17\">",
"      Babady NE, Buckwalter SP, Hall L, et al. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J Clin Microbiol 2011; 49:3204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/18\">",
"      Bialek R, Cirera AC, Herrmann T, et al. Nested PCR assays for detection of Blastomyces dermatitidis DNA in paraffin-embedded canine tissue. J Clin Microbiol 2003; 41:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/19\">",
"      Tang YW, Li H, Durkin MM, et al. Urine polymerase chain reaction is not as sensitive as urine antigen for the diagnosis of disseminated histoplasmosis. Diagn Microbiol Infect Dis 2006; 54:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/20\">",
"      Goodwin RA Jr, Owens FT, Snell JD, et al. Chronic pulmonary histoplasmosis. Medicine (Baltimore) 1976; 55:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/21\">",
"      Loyd JE, Tillman BF, Atkinson JB, Des Prez RM. Mediastinal fibrosis complicating histoplasmosis. Medicine (Baltimore) 1988; 67:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/22\">",
"      Peikert T, Colby TV, Midthun DE, et al. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltimore) 2011; 90:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/23\">",
"      Davis AM, Pierson RN, Loyd JE. Mediastinal fibrosis. Semin Respir Infect 2001; 16:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/24\">",
"      Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/25\">",
"      Johnson PC, Wheat LJ, Cloud GA, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med 2002; 137:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/26\">",
"      Dismukes WE, Bradsher RW Jr, Cloud GC, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med 1992; 93:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/27\">",
"      McKinsey DS, Kauffman CA, Pappas PG, et al. Fluconazole therapy for histoplasmosis. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1996; 23:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/28\">",
"      Wheat LJ, Connolly P, Smedema M, et al. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis 2001; 33:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/29\">",
"      Restrepo A, Tob&oacute;n A, Clark B, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect 2007; 54:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/30\">",
"      Freifeld AG, Iwen PC, Lesiak BL, et al. Histoplasmosis in solid organ transplant recipients at a large Midwestern university transplant center. Transpl Infect Dis 2005; 7:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/31\">",
"      Freifeld A, Proia L, Andes D, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother 2009; 53:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/32\">",
"      Putnam, LR, Sutliff, WD, Larkin, JC, et al. Histoplasmosis cooperative study: Chronic pulmonary histoplasmosis treated with amphotericin B alone and with amphotericin B and triple sulfonamide. Am Rev Respir Dis 1968; 97:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/33\">",
"      Hammoud ZT, Rose AS, Hage CA, et al. Surgical management of pulmonary and mediastinal sequelae of histoplasmosis: a challenging spectrum. Ann Thorac Surg 2009; 88:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/34\">",
"      Goodwin RA, Nickell JA, Des Prez RM. Mediastinal fibrosis complicating healed primary histoplasmosis and tuberculosis. Medicine (Baltimore) 1972; 51:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/35\">",
"      Doyle TP, Loyd JE, Robbins IM. Percutaneous pulmonary artery and vein stenting: a novel treatment for mediastinal fibrosis. Am J Respir Crit Care Med 2001; 164:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/36\">",
"      Albers EL, Pugh ME, Hill KD, et al. Percutaneous vascular stent implantation as treatment for central vascular obstruction due to fibrosing mediastinitis. Circulation 2011; 123:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/37\">",
"      Goodwin RA Jr, Snell JD Jr. The enlarging histoplasmoma. Concept of a tumor-like phenomenon encompassing the tuberculoma and coccidioidoma. Am Rev Respir Dis 1969; 100:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/38\">",
"      Wheat LJ, Stein L, Corya BC, et al. Pericarditis as a manifestation of histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983; 62:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/39\">",
"      Picardi JL, Kauffman CA, Schwarz J, et al. Pericarditis caused by Histoplasma capsulatum. Am J Cardiol 1976; 37:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21881/abstract/40\">",
"      Rosenthal J, Brandt KD, Wheat LJ, Slama TG. Rheumatologic manifestations of histoplasmosis in the recent Indianapolis epidemic. Arthritis Rheum 1983; 26:1065.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2451 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-5115C1355F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21881=[""].join("\n");
var outline_f21_23_21881=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHEN TO SUSPECT HISTOPLASMOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histopathology and cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fungal cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antigen detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Comparison of serologic methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H352373898\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Distinction from sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SELECTION OF DIAGNOSTIC TESTS FOR DIFFERENT PULMONARY SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute diffuse pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Acute localized pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Chronic cavitary pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mediastinal syndromes, broncholithiasis, and lung nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANTIFUNGAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Itraconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      THERAPY FOR PULMONARY HISTOPLASMOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Acute diffuse pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H253380950\">",
"      Acute localized pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Chronic cavitary pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Granulomatous mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Fibrosing mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Broncholithiasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Pulmonary nodules (histoplasmomas)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      EXTRAPULMONARY MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Pericarditis or rheumatologic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2451|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/34/21038\" title=\"figure 1\">",
"      Histo dx test sensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2451|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/36/5699\" title=\"picture 1\">",
"      Histoplasmosis lung granuloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/55/43888\" title=\"picture 2\">",
"      Histoplasmosis silver stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/58/30636\" title=\"table 1\">",
"      Rx recs pulm histo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/5/38998?source=related_link\">",
"      Amphotericin B nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9321?source=related_link\">",
"      Diagnosis and treatment of disseminated histoplasmosis in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1449?source=related_link\">",
"      Diagnosis and treatment of histoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15526?source=related_link\">",
"      Fibrosing mediastinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42376?source=related_link\">",
"      Pathogenesis and clinical features of pulmonary histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/5/13393?source=related_link\">",
"      Patient information: Histoplasmosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/43/11961?source=related_link\">",
"      Treatment of pulmonary sarcoidosis with glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_23_21882="Preeclampsia: Management and prognosis";
var content_f21_23_21882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preeclampsia: Management and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21882/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21882/contributors\">",
"     John T Repke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21882/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21882/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/23/21882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/23/21882/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/23/21882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia refers to the new onset of hypertension and proteinuria after 20 weeks of gestation in a previously normotensive woman (",
"    <a class=\"graphic graphic_table graphicRef79977 \" href=\"UTD.htm?4/31/4603\">",
"     table 1",
"    </a>",
"    ). It can be classified as mild or severe (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ). Delivery results in resolution of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31268781\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive treatment of preeclampsia is delivery to prevent development of maternal or fetal complications from disease progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H1564260#H1564260\">",
"     \"Preeclampsia: Clinical features and diagnosis\", section on 'Burden of disease'",
"    </a>",
"    .) Whether or not to deliver the fetus is based upon gestational age, the severity of preeclampsia, and maternal and fetal condition. Patients with mild or severe preeclampsia at or near term are delivered; however, remote from term, the risks of serious sequelae from disease progression need to be weighed against the risks of preterm birth. Evidence of serious maternal end-organ dysfunction or nonreassuring tests of fetal well-being are indications for prompt delivery at any gestational age. On the other hand, when mother and fetus are stable, a conservative approach is reasonable in order to achieve further fetal growth and maturity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31268819\">",
"    <span class=\"h1\">",
"     APPROACH BASED ON DISEASE SEVERITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31268927\">",
"    <span class=\"h2\">",
"     Severe preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe preeclampsia (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ) is generally regarded as an indication for delivery, regardless of gestational age, in order to minimize the risk of development of serious maternal and fetal complications (eg, cerebral hemorrhage, hepatic rupture, renal failure, pulmonary edema, seizure, bleeding related to thrombocytopenia, fetal growth restriction, abruptio placentae) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. With the exception of fetal growth restriction, any of these adverse events can occur suddenly in a woman with severe disease. However, if proteinuria &ge;5 grams is the only criteria for severe disease, patients are usually managed as mild preeclamptics since the amount of proteinuria has no correlation with risk of adverse maternal or perinatal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link&amp;anchor=H2263119#H2263119\">",
"     \"Expectant management of severe preeclampsia\", section on 'Severe preeclampsia based solely on proteinuria'",
"    </a>",
"    .) Similarly, if the only criteria for severe disease is (1) mild fetal growth restriction with reassuring Doppler velocimetry or (2) severe hypertension, then a conservative approach may be considered remote from term. These clinical scenarios are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link&amp;anchor=H2263126#H2263126\">",
"     \"Expectant management of severe preeclampsia\", section on 'Severe preeclampsia based solely on fetal growth restriction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link&amp;anchor=H2263133#H2263133\">",
"     \"Expectant management of severe preeclampsia\", section on 'Severe preeclampsia based solely on blood pressure criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Observational data suggest that the decision to expedite delivery in the setting of severe preeclampsia does not mandate immediate cesarean birth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Cervical ripening agents can be used prior to induction if the cervix is not favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/11\">",
"     11",
"    </a>",
"    ]. However, we feel that a prolonged induction and inductions with a low likelihood of success are best avoided. Cesarean delivery is reasonable for women with severe preeclampsia who are under 30 weeks of gestation and have a low Bishop score, given the high frequency of nonreassuring fetal heart rate tracings and failure of the cervix to dilate in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Only about one-third of preterm inductions result in vaginal birth.",
"   </p>",
"   <p>",
"    Prolongation of pregnancy in a tertiary care setting or in consultation with a maternal-fetal medicine specialist is an option for selected women remote from term (&lt;34 weeks of gestation). Candidates for this approach and their management (eg, antenatal corticosteroids for fetal lung maturation) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link\">",
"     \"Expectant management of severe preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mild preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experts consistently recommend delivery of women with mild preeclampsia at &ge;37 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/4,14,15\">",
"     4,14,15",
"    </a>",
"    ]. Cervical ripening agents should be used in women with unfavorable cervices.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefits of labor induction at &ge;37 weeks of gestation were illustrated in a multicenter trial (HYPITAT) that randomly assigned 756 women with mild preeclampsia or gestational hypertension",
"      <span class=\"nowrap\">",
"       &gt;36",
"       <sup>",
"        0/7",
"       </sup>",
"      </span>",
"      weeks to induction of labor or expectant management with",
"      <span class=\"nowrap\">",
"       maternal/fetal",
"      </span>",
"      monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/16\">",
"       16",
"      </a>",
"      ]. Routine induction was associated with a significant reduction in composite adverse maternal outcome (RR 0.71, 95% CI 0.59-0.86; absolute risk reduction 12.76 percent), which was primarily driven by a reduction in patients who developed severe hypertension and was not significant for women at 36",
"      <sup>",
"       0",
"      </sup>",
"      to 36",
"      <sup>",
"       6",
"      </sup>",
"      weeks. The induced group delivered, on average, 1.2 weeks earlier than the control group and had a significantly lower rate of cesarean delivery (14 versus 19 percent). There were no significant differences between groups in neonatal outcome.",
"      <br/>",
"      <br/>",
"      This trial showed that preeclamptic women benefited from early intervention, without incurring an increased risk of operative delivery or neonatal morbidity. The trial was not large enough to determine whether small differences in newborn outcomes or induction between 36 and 37 weeks might be statistically significant. A follow-up economic analysis of this trial concluded induction was also less costly overall than expectant management with monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/17\">",
"       17",
"      </a>",
"      ]. Another follow-up analysis showed that an unfavorable cervix was not a reason to avoid induction [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimum management for women with mild preeclampsia and stable maternal and fetal conditions at",
"    <span class=\"nowrap\">",
"     34",
"     <sup>",
"      0/7",
"     </sup>",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     36",
"     <sup>",
"      0/7",
"     </sup>",
"    </span>",
"    weeks remains uncertain; no randomized trials have been performed in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/19\">",
"     19",
"    </a>",
"    ]. These pregnancies are generally managed expectantly to enable further fetal growth and maturation. Progression of the disease is generally slow and observational data show that many patients with late onset disease will reach term with only mild disease. For patients managed expectantly, delivery is indicated as soon as they develop signs or symptoms of severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ) or at 37 weeks of gestation if the disease does not progress to this stage.",
"   </p>",
"   <p>",
"    Prior to",
"    <span class=\"nowrap\">",
"     34",
"     <sup>",
"      0/7",
"     </sup>",
"    </span>",
"    weeks, guidelines from major medical organizations generally recommend expectant management of mild preeclampsia, based on expert opinion, given the high risk of complications of prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/4,19\">",
"     4,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"     \"Short-term complications of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13814?source=see_link\">",
"     \"Long-term complications of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=see_link\">",
"     \"Incidence and mortality of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703219\">",
"    <span class=\"h1\">",
"     EXPECTANT ANTEPARTUM MANAGEMENT OF MILD PREECLAMPSIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Inpatient versus outpatient care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close maternal monitoring upon diagnosis of preeclampsia is important to establish disease severity and the rate of progression. Hospitalization is useful for making these assessments and facilitates rapid intervention in the event of rapid progression. After the initial diagnostic evaluation, outpatient care is a cost-effective option for women with stable mild preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. Outpatient care can be provided in the patient&rsquo;s home or, where available, at an antenatal day care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data on outcome of outpatient management of preeclamptic women. An observational study and a randomized trial reported good outcomes, but these studies had too few subjects to detect clinically significant differences in outcome between inpatient and outpatient management [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A systematic review of three trials with a total of 504 women with various complications of pregnancy observed no major differences in clinical outcomes for mothers or babies between antenatal day units or hospital admission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients offered outpatient monitoring should be able to comply with frequent maternal and fetal evaluations (every one to three days) and should have ready access to medical care. Restricted activity is typically recommended since blood pressure is lower in rested patients; however, there is no evidence that bedrest improves pregnancy outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/26\">",
"     26",
"    </a>",
"    ]. Rest in the left lateral decubitus position can augment uteroplacental flow, which may benefit some pregnancies. If signs or symptoms of disease progression are noted, hospitalization for more intensive monitoring and possible delivery is indicated.",
"   </p>",
"   <p>",
"    Patients should be told to call their health care provider immediately if they develop severe or persistent headache, visual changes, right upper quadrant or epigastric pain, nausea or vomiting, shortness of breath, significant weight gain over one to two days, or decreased urine output [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/27\">",
"     27",
"    </a>",
"    ]. As with any pregnancy, decreased fetal movement, vaginal bleeding, abdominal pain, rupture of membranes, or uterine contractions should be reported immediately, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The minimum laboratory evaluation should include platelet count, serum creatinine, and serum AST. These tests should be repeated once or twice weekly in women with mild preeclampsia to assess for disease progression, and more often if clinical signs and symptoms suggest worsening disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of other tests is less clearly defined. A rising hematocrit can be useful to look for hemoconcentration, which suggests contraction of intravascular volume and progression to more severe disease, while a falling hematocrit may be a sign of hemolysis. An elevated serum indirect bilirubin concentration is a better sign of hemolysis, although an elevated LDH may also be a marker of severe disease or HELLP syndrome. Hemolysis can be confirmed by observation of schistocytes and helmet cells on a blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 graphicRef50715 \" href=\"UTD.htm?34/52/35657\">",
"     picture 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Since several clinical studies have shown that neither the rate of increase nor the amount of proteinuria affects maternal or perinatal outcome in the setting of preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/5-8\">",
"     5-8",
"    </a>",
"    ], repeated 24-hour urinary protein estimations are not useful once the threshold of 300",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours for the diagnosis of preeclampsia has been exceeded. Serum creatinine alone can be used to monitor renal function. When required, quantification of protein excretion can be performed using a 24-hour collection or protein-to creatinine ratio on a random specimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link\">",
"     \"Expectant management of severe preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antihypertensive drugs to control mildly elevated blood pressure in the setting of preeclampsia does not alter the course of the disease or diminish perinatal morbidity or mortality, and should be avoided. The indications for starting antihypertensive therapy, the choice of drug, and blood pressure goals are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Preeclampsia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sodium restriction below the recommended daily intake and diuretics have no role in routine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Although intravascular vascular volume is reduced, a randomized trial showed that plasma volume expansion did not improve maternal or fetal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Assessment of fetal well-being",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data from randomized trials on which to base recommendations for the optimal type and frequency of fetal biophysical monitoring. We suggest daily fetal movement counts and twice weekly fetal nonstress testing with assessment of amniotic fluid volume, or twice weekly biophysical profiles. Testing is repeated immediately if there is an abrupt change in maternal condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=see_link\">",
"     \"Antepartum fetal heart rate assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of umbilical artery Doppler indices is also useful, as the results help in optimal timing of delivery. In a meta-analysis of 16 randomized trials in high risk pregnancies, knowledge of umbilical artery Doppler velocimetry results was associated with a 29 percent reduction in perinatal death (RR 0.71, 95% CI 0.52-0.98, 10,225 babies, 1.2 versus 1.7 percent; number needed to treat 203, 95%CI 103- 4352), primarily in pregnancies complicated by preeclampsia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    growth restriction. The frequency of assessment depends on the findings; weekly assessment is reasonable when Doppler indices are normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link&amp;anchor=H12#H12\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\", section on 'Clinical effectiveness'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link&amp;anchor=H13#H13\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\", section on 'Guidelines for clinical practice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Assessment of fetal growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early fetal growth restriction may be the first manifestation of preeclampsia and is a criterion of severe disease. We suggest sonographic estimation of fetal weight be performed to look for growth restriction and oligohydramnios at the time of diagnosis of preeclampsia and then repeated every three weeks if the initial examination is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/27\">",
"     27",
"    </a>",
"    ]. If fetal growth is suboptimal, the frequency can be increased. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link&amp;anchor=H4#H4\">",
"     \"Fetal growth restriction: Evaluation and management\", section on 'Serial fetal weight assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antenatal corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preeclampsia may accelerate fetal lung maturation, neonatal respiratory distress remains common in premature neonates of preeclamptic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Antenatal corticosteroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    ) to promote fetal lung maturity should be administered to women less than 34 weeks of gestation since they are at increased risk of progression to severe disease and preterm delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703332\">",
"    <span class=\"h1\">",
"     INTRAPARTUM MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intrapartum monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous maternal-fetal monitoring is indicated intrapartum to identify worsening hypertension, deteriorating maternal hepatic, renal, cardiopulmonary, neurological, or hematologic function, as well as abruptio placentae or a nonreassuring fetal heart rate tracing. There are no evidence-based standards for the optimal approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H961072\">",
"    <span class=\"h2\">",
"     Fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluid balance should be monitored closely to avoid excessive administration, since women with severe disease are at risk of pulmonary edema and significant third-spacing. Maintenance fluids of 80",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    are often adequate in the absence of ongoing fluid loss, such as bleeding. Oliguria that does not respond to a modest trial of increased fluids should be tolerated. Diuretics are only indicated for treatment of pulmonary edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H961079\">",
"    <span class=\"h2\">",
"     Management of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hypertension is treated with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Acute therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704577\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuraxial techniques are generally safe and effective in preeclamptic women [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/34\">",
"     34",
"    </a>",
"    ]. In preeclampsia, the two major anesthesia-related concerns with use of neuraxial techniques are (1) the potential for a large drop in blood pressure due to depleted intravascular volume and sympathetic blockade and (2) peridural hematoma in women with severe thrombocytopenia. The former can be minimized by appropriate adjustments in pre-hydration, drug choice, drug dosing, and drug delivery by the anesthesiologist; however, a low platelet count may preclude neuraxial anesthesia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H6#H6\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Hypotension'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=see_link&amp;anchor=H12561208#H12561208\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\", section on 'Neuraxial analgesia and low platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major concerns associated with general anesthesia (for cesarean delivery) are a transient spike in blood pressure during intubation (response to noxious stimuli), hypotension (from reduction in cardiac output and systemic vascular resistance), and difficult or failed intubation because of oropharyngeal edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34248?source=see_link\">",
"     \"Airway management of pregnant women at delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these issues, early patient assessment by the anesthesia team is desirable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Invasive hemodynamic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive hemodynamic monitoring can be useful in complicated patients, such as those with severe cardiac disease, severe renal disease, severe oliguria, refractory hypertension, or pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/1\">",
"     1",
"    </a>",
"    ]. However, most women can be managed without these tools and should not be exposed to the risks associated with arterial and central venous catheterization. Randomized trials have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Seizure prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon data from randomized trials, we administer intrapartum",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    seizure prophylaxis to women with mild or severe preeclampsia. Although seizure and death are rare outcomes after non-treatment of mild preeclampsia, we feel the benefit of treatment is justifiable given the low cost and toxicity of magnesium sulfate and the relatively low number of patients that need to be treated to prevent one seizure. In a randomized placebo-controlled trial including 10,000 women (MAGPIE [magnesium sulfate for prevention of eclampsia trial]), about 100 women with mild preeclampsia and about 60 women with severe preeclampsia would need to be treated to prevent one seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to emphasize that seizure prophylaxis does not prevent progression of disease unrelated to convulsions. Approximately 10 to 15 percent of women in labor with mild preeclampsia will develop signs of severe preeclampsia (eg, severe hypertension, severe headache, visual disturbance, epigastric pain, laboratory abnormalities) or abruptio placenta, whether or not they receive magnesium therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not administer seizure prophylaxis to women with gestational hypertension alone, as the seizure risk in the latter group is less than 0.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=see_link\">",
"     \"Gestational hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Magnesium sulfate versus other anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major medical organizations worldwide consistently recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    as the drug of choice for the prevention of eclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/1,19,40\">",
"     1,19,40",
"    </a>",
"    ]. In randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/36,41,42\">",
"     36,41,42",
"    </a>",
"    ] and large observational series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/43\">",
"     43",
"    </a>",
"    ], magnesium sulfate was more effective for prevention of a first seizure than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/41\">",
"     41",
"    </a>",
"    ] or an antihypertensive drug alone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/20/16710?source=see_link\">",
"     nimodipine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/42\">",
"     42",
"    </a>",
"    ] or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/43\">",
"     43",
"    </a>",
"    ]. As an example, a trial that randomly assigned 2138 preeclamptic patients admitted to Labor and Delivery at Parkland Hospital to seizure prophylaxis with magnesium sulfate or phenytoin reported eclamptic seizures in 10 of 1089 women assigned to phenytoin compared to none of 1049 women assigned to magnesium sulfate [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/41\">",
"     41",
"    </a>",
"    ]. Maternal and neonatal outcomes were similar in both groups.",
"   </p>",
"   <p>",
"    In meta-analyses of randomized trials in eclamptic women,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    was safer and more effective for prevention of recurrent seizures than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , or lytic cocktail (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    , and pethidine). These data provide additional indirect evidence of its effectiveness in preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link&amp;anchor=H13#H13\">",
"     \"Eclampsia\", section on 'Prevention of recurrent convulsions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Magnesium regimen and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the optimal magnesium regimen, when it should be started and terminated, or route of administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/44\">",
"     44",
"    </a>",
"    ]. The drug is usually initiated at the onset of labor or induction, or prior to cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. It is usually not given to stable antepartum patients off the labor unit, but is sometimes used in women with severe preeclampsia being considered for expectant management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=see_link\">",
"     \"Expectant management of severe preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704368\">",
"    <span class=\"h4\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although published dosage regimens for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    vary widely (loading dose of 4 to 6 grams intravenously and maintenance dose of 1 to 3 grams per hour), the most common regimen, and the one that we use, is a loading dose of 6 grams intravenously over 15 to 20 minutes followed by 2 grams per hour as a continuous infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/1,38,43,46\">",
"     1,38,43,46",
"    </a>",
"    ]. An alternative regimen is 5 grams intramuscularly into each buttock (total of 10 grams) followed by 5 grams intramuscularly every four hours. However, this method is associated with more side effects, particularly pain at the injection site.",
"   </p>",
"   <p>",
"    There does not appear to be a clear threshold concentration for insuring the prevention of convulsions, although a therapeutic range of 4.8 to 8.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.0 to 3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    has been recommended based on retrospective data [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/47\">",
"     47",
"    </a>",
"    ]. Loading doses less than 6 grams are more likely to result in subtherapeutic magnesium levels (less than 4.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/43,48\">",
"     43,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    is excreted by the kidneys, dosing should be adjusted in women with renal insufficiency (defined as a serum creatinine greater than 1.0",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    Such women should receive a standard loading dose (since their volume of distribution is not altered), but a reduced maintenance dose (1 gram per hour or no maintenance dose if the serum creatinine is greater than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    and close monitoring of their serum magnesium level every six hours.",
"   </p>",
"   <p>",
"    The maintenance phase is given only if a patellar reflex is present (loss of reflexes being the first manifestation of symptomatic hypermagnesemia), respirations exceed 12 per minute, and the urine output exceeds 100 mL per four hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link\">",
"     \"Symptoms of hypermagnesemia\"",
"    </a>",
"    .) Following serum magnesium levels is not required if the woman's clinical status is closely monitored for evidence of potential magnesium toxicity (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Complications and side effects'",
"    </a>",
"    below). The maintenance dose should be decreased if there is clinical evidence of magnesium toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H704472\">",
"    <span class=\"h4\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is usually continued for 24 hours postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/46\">",
"     46",
"    </a>",
"    ]. Timing of drug discontinuation has been arbitrary; there are no high quality data to guide therapy. In women who have only mild preeclampsia, discontinuation of therapy after 12 hours may be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/49\">",
"     49",
"    </a>",
"    ]. In women with severe preeclampsia or eclampsia, seizure prophylaxis is generally continued for 24 to 48 hours postpartum, after which the risk of recurrent seizures is low.",
"   </p>",
"   <p>",
"    It is probably reasonable to extend the duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    therapy in women whose disease has not begun to improve postpartum and shorten the duration of therapy in women who are clearly improving clinically (eg, diuresis of &ge;100",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    for two consecutive hours, absence of symptoms [headache, visual changes, epigastric pain], and absence of severe hypertension) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. Diuresis (greater than 4",
"    <span class=\"nowrap\">",
"     L/day)",
"    </span>",
"    is believed to be the most accurate clinical indicator of resolution of",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    but is not a guarantee against the development of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/54\">",
"     54",
"    </a>",
"    ]. In women with persistent renal impairment postpartum, it is important to be cautious when administering a prolonged magnesium sulfate infusion to prevent the occurrence of magnesium toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h4\">",
"     Complications and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid infusion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    causes diaphoresis, flushing, and warmth, probably related to peripheral vasodilation and a drop in blood pressure. Nausea, vomiting, headache, muscle weakness, visual disturbances, and palpitations can also occur. Dyspnea or chest pain may be symptoms of pulmonary edema, which is a rare side effect. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link\">",
"     \"Symptoms of hypermagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnesium toxicity is uncommon in women with good renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/55\">",
"     55",
"    </a>",
"    ]. Toxicity is related to serum magnesium concentration: loss of deep tendon reflexes occurs at 9.6 to 12.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.0 to 5.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respiratory paralysis at 12.0 to 18.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5 to 7.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and cardiac arrest at 24 to 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10 to 12.5",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     Calcium gluconate",
"    </a>",
"    (1 gram intravenously over 5 to 10 minutes) should be administered only to counteract life-threatening symptoms of magnesium toxicity (such as cardiorespiratory compromise).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     Magnesium sulfate",
"    </a>",
"    is contraindicated in women with myasthenia gravis since it can precipitate a severe myasthenic crisis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=see_link\">",
"     \"Management of myasthenia gravis in pregnancy\"",
"    </a>",
"    ). Neuromuscular blockade and hypotension due to concurrent use of magnesium sulfate and calcium channel blockers have been described in case reports, but the risk appears to be minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    is a weak tocolytic, labor duration does not appear to be affected by magnesium sulfate administration [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/57\">",
"     57",
"    </a>",
"    ]. The risk of postpartum hemorrhage, possibly related to uterine atony from magnesium's tocolytic effects, was slightly increased in one trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnesium freely crosses the placenta; as a result, the cord blood concentration approximates the maternal serum concentration. Maternal therapy causes a decrease in baseline fetal heart rate, which generally remains within the normal range, and a decrease in fetal heart rate variability, which may be absent or minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/58\">",
"     58",
"    </a>",
"    ]. Antenatal fetal assessment test results (eg, biophysical profile score and nonstress test reactivity) are not significantly altered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnesium therapy results in a transient reduction of total and ionized serum calcium concentration due to rapid suppression of parathyroid hormone release [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/60\">",
"     60",
"    </a>",
"    ]. Rarely, hypocalcemia becomes symptomatic (myoclonus, delirium, ECG abnormalities). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link&amp;anchor=H4#H4\">",
"     \"Symptoms of hypermagnesemia\", section on 'Hypocalcemia'",
"    </a>",
"    .) Cessation of magnesium therapy will restore normal serum calcium levels. However, calcium administration may be required if symptoms are present (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    1 gram intravenously over 5 to 10 minutes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=see_link\">",
"     \"Causes and treatment of hypermagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8632592\">",
"    <span class=\"h4\">",
"     Mechanism of anticonvulsant action",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism for the anticonvulsant effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    has not been clearly defined. The primary effect is thought to be central. Hypotheses include action at the n-methyl d-aspartate (NMDA) receptor that raises the seizure threshold, membrane stabilization in the central nervous system secondary to its actions as a non-specific calcium channel blocker, as well as decreasing acetylcholine in motor nerve terminals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Another theory is that it promotes vasodilatation of constricted cerebral vessels by opposing calcium-dependent arterial vasospasm, thereby reducing cerebral barotrauma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     POSTPARTUM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) for pain control should be avoided in women with poorly controlled hypertension, oliguria, renal insufficiency, or thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no evidence-based standards for the optimal approach to postpartum monitoring and follow-up. We monitor vital signs every two hours while the patient remains on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    and we repeat laboratory tests until two consecutive sets of data are normal.",
"   </p>",
"   <p>",
"    Severe hypertension should be treated; some patients will have to be discharged on antihypertensive medications, which are discontinued when blood pressure returns to normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H523716270#H523716270\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Postpartum hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should be followed closely as outpatients until complete resolution of hypertension and laboratory abnormalities. Alternative diagnoses should be sought in those with persistent abnormal findings after three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link\">",
"     \"Overview of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H960515\">",
"    <span class=\"h1\">",
"     GUIDELINES FROM SELECTED ORGANIZATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of medical organizations have published guidelines for management of preeclampsia. These guidelines are generally consistent with the recommendations in this topic review.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American College of Obstetricians and Gynecologists (ACOG). Practice bulletin: Diagnosis and management of preeclampsia and eclampsia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      National Institute for Health and Clinical Excellence (NICE). Hypertension in pregnancy: The management of hypertensive disorders during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Society of Obstetricians and Gynaecologists of Canada (SOGC). Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21332929\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognostic issues include the risk of recurrent preeclampsia and related complications in subsequent pregnancies and long-term maternal health risks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21332951\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recurrence risk varies with the severity and time of onset of the acute episode [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/65\">",
"     65",
"    </a>",
"    ]. Women with early onset, severe preeclampsia are at greatest risk of recurrence (as high as 25 to 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. The risk is much lower (5 to 7 percent) in women who had mild preeclampsia during the first pregnancy, versus less than 1 percent in women who had a normotensive first pregnancy (does not apply to abortions) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/66,69-74\">",
"     66,69-74",
"    </a>",
"    ]. The occurrence of preeclampsia in future pregnancies is best illustrated by the following prospective study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 125 women with severe second trimester preeclampsia followed for five years, 65 percent developed recurrent preeclampsia and 35 percent were normotensive in their subsequent pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/66\">",
"       66",
"      </a>",
"      ]. Of the preeclamptic group, approximately one-third developed the disease at &le;27 weeks, one-third at 28 to 36 weeks, and one-third at &ge;37 weeks. Thus, 21 percent of subsequent pregnancies were complicated by severe preeclampsia in the second trimester.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent preeclampsia is more likely following a preeclamptic singleton pregnancy than a preeclamptic twin pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/75\">",
"     75",
"    </a>",
"    ]. The recurrence risk in women with HELLP syndrome (who may develop either HELLP or preeclampsia in a subsequent pregnancy) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707032\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive therapy is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link\">",
"     \"Prevention of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707006\">",
"    <span class=\"h2\">",
"     Risk of related obstetrical complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia, growth restriction, preterm delivery, abruptio placentae, and stillbirth can all be sequelae of impaired placental function. Women with pregnancies complicated by one of these disorders are at increased risk of developing one of the other disorders in future pregnancies. Early onset preeclampsia is more likely to be associated with one of these adverse events in a subsequent pregnancy, even if normotensive, than late onset preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21332965\">",
"    <span class=\"h2\">",
"     Long-term maternal risks",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21332973\">",
"    <span class=\"h3\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case-control and cohort studies consistently report that preeclampsia is predictive of future cardiovascular and cerebrovascular disease. This risk was summarized in two systematic reviews of controlled studies that evaluated the risk of late cardiovascular events in women with and without a history of preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared with women with no history of the disease, women with preeclampsia were at increased risk of developing hypertension (RR 3.70, 95% CI 2.70-5.05 at mean follow-up of 14 years), ischemic heart disease (RR 2.16, 95% CI 1.86-2.52 at mean follow-up of 11.7 years), stroke (RR 1.81, 95% CI 1.45-2.27 at mean follow-up of 10.4 years), and venous thromboembolism (RR 1.79, 95% CI 1.37-2.33 at mean follow-up of 4.7 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/78\">",
"       78",
"      </a>",
"      ]. The absolute risk that a woman with or without a history of preeclampsia would develop one of these cardiovascular events at age 50 to 59 years was estimated to be 17.8 and 8.3 percent, respectively.",
"     </li>",
"     <li>",
"      In addition, a graded relationship was observed between severity of preeclampsia and risk of future cardiac disease (mild preeclampsia RR 2.00, 95% CI 1.83-2.19; moderate preeclampsia RR 2.99, 95% CI 2.51-3.58; severe preeclampsia RR 5.36, 95% CI 3.96-7.27), as well as a correlation between preeclampsia and future peripheral artery disease (RR 1.87, 95% CI",
"      <span class=\"nowrap\">",
"       0/94-3.73)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/79\">",
"       79",
"      </a>",
"      ]. The authors defined preeclampsia as 'mild' if the pregnancy had an uncomplicated course, 'moderate' if preeclampsia was complicated by fetal growth restriction or maternal seizures and 'severe' if preeclampsia was complicated by preterm delivery or fetal demise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A large prospective cohort study (Avon Longitudinal Study of Parents and Children, ALSPAC) published after these reviews reported similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with early",
"    <span class=\"nowrap\">",
"     onset/severe",
"    </span>",
"    preeclampsia with preterm delivery are at highest risk of cardiovascular disease later in life, including during the premenopausal period (",
"    <a class=\"graphic graphic_table graphicRef76674 \" href=\"UTD.htm?4/37/4699\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/81\">",
"     81",
"    </a>",
"    ]. In contrast, mild preeclampsia occurring late in gestation does not appear to be associated with a high risk of remote cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/82\">",
"     82",
"    </a>",
"    ]. The stronger association between cardiovascular disease and preterm preeclampsia suggests that the pathogenesis of early versus late preeclampsia may be different.",
"   </p>",
"   <p>",
"    Several studies have demonstrated that women with a history of preeclampsia or severe early onset fetal growth restriction exhibit impaired endothelial function and vasodilatation remote from pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/83-86\">",
"     83-86",
"    </a>",
"    ]. Women with a history of hypertensive disorders in pregnancy have higher levels of glucose, insulin, and unfavorable lipids than women with a history of normotensive pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/87\">",
"     87",
"    </a>",
"    ]. Data from some epidemiologic studies suggest that the increased risk of late cardiovascular morbidity in previously preeclamptic women reflects an underlying predisposition in these women for both disorders, but it is also possible that preeclampsia results in permanent arterial changes leading to late cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. Some investigators have hypothesized that increased insulin resistance, sympathetic overactivity, proinflammatory activity, endothelial dysfunction, and the abnormal lipid profile in preeclamptic women constitute an early manifestation of metabolic syndrome and that these changes persist after pregnancy, thereby putting affected woman at increased risk of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/91-94\">",
"     91-94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21332980\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a large registry-based cohort study, gestational hypertension or preeclampsia in a first pregnancy was associated with a three- to four-fold increase in risk for subsequent development of type 2 diabetes mellitus compared with women with no hypertensive disorder in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21332987\">",
"    <span class=\"h3\">",
"     End-stage renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with preeclampsia may be at increased risk of developing end-stage renal disease (ESRD) later in life, but the absolute risk is small. A study that linked four decades of data from the Norwegian national birth and ESRD registries found that women with preeclampsia in their first pregnancy had a four-fold increase in risk of ESRD compared with women without preeclampsia (RR 4.7, 95% CI 3.6-6.1) after adjusting for known confounders, but the absolute risk of ESRD was less than 1 percent within 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/96\">",
"     96",
"    </a>",
"    ]. Similarly, a study using claims data from the Taiwan National Health Insurance Program noted that women with",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    were at significantly higher risk of developing ESRD over time than women without hypertensive disorders during pregnancy (incidence 5.33 versus 0.34 per 10,000 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although women who went on to develop ESRD may have had subclinical renal disease during pregnancy, it is also possible that as yet undefined risk factors predisposed these women to both preeclampsia and ESRD. It is less likely that preeclampsia damages the kidney, thereby initiating a process of chronic deterioration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H707175\">",
"    <span class=\"h3\">",
"     Subclinical hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;A nested case-control study found that nulliparous women who developed preeclampsia were twice as likely to develop subclinical hypothyroidism during pregnancy and long after delivery than matched normotensive controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/98\">",
"     98",
"    </a>",
"    ]. The risk was strongest in women with recurrent preeclampsia and without thyroid peroxidase antibodies, suggesting that an autoimmune mediated mechanism of hypothyroidism was not involved. In a study including 25,000 pregnant women, women with subclinical hypothyroidism identified during pregnancy were at increased risk of developing severe preeclampsia compared with euthyroid women (OR 1.6, 95% CI 1.1-2.4), after adjustment for risk factors for preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/99\">",
"     99",
"    </a>",
"    ]. Abnormal levels of thyroid hormones appear to damage endothelial cells, potentially leading to preeclampsia and long-term cardiovascular sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21332994\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review found",
"    <strong>",
"     no",
"    </strong>",
"    significant association between preeclampsia and later development of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/78\">",
"     78",
"    </a>",
"    ]. Observational studies from the United States, Sweden, and Norway reported that women with preeclampsia were at reduced risk or had no excess risk of cancer when followed 13 to 19 years postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/81,100-105\">",
"     81,100-105",
"    </a>",
"    ]. In contrast, a study from Israel reported an increased risk of cancer in such women (hazard ratio 1.27, 95% CI 1.03-1.57) with a median follow-up of 29 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/23/21882/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Site-specific increases were noted for cancer of the stomach, lung or larynx, breast, and ovary. The discordant results may be explained by a number of factors, including differences in patient populations, absence of or insufficient adjustment for confounders, differences in length of follow-up, and incomplete ascertainment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/53/28498?source=see_link\">",
"       \"Patient information: Preeclampsia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=see_link\">",
"       \"Patient information: High blood pressure and pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29410?source=see_link\">",
"       \"Patient information: HELLP syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"       \"Patient information: Preeclampsia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The definitive treatment of preeclampsia is delivery to prevent development of maternal or fetal complications from disease progression. Timing of delivery is based upon gestational age, the severity of preeclampsia, and maternal and fetal condition. (See",
"      <a class=\"local\" href=\"#H31268781\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe preeclampsia (",
"      <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"       table 2",
"      </a>",
"      ) is generally regarded as an indication for delivery, regardless of gestational age, given the high risk of serious maternal morbidity. However, prolonged antepartum management in a tertiary care setting or in consultation with a maternal-fetal medicine specialist is an option for selected women remote from term (&lt;34 weeks of gestation). (See",
"      <a class=\"local\" href=\"#H31268927\">",
"       'Severe preeclampsia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with mild preeclampsia, we suggest expectant management with delivery at &ge;37 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mild preeclampsia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Expectant management of women with mild preeclampsia consists of frequent laboratory monitoring (platelet count, liver and renal function tests), assessment of maternal blood pressure and symptoms, and evaluation of fetal growth and well-being. (See",
"      <a class=\"local\" href=\"#H703219\">",
"       'Expectant antepartum management of mild preeclampsia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with preeclampsia between 23 and 34 weeks of gestation, we recommend a course of antenatal glucocorticoids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link\">",
"       \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with severe preeclampsia, we recommend seizure prophylaxis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The benefit of seizure prophylaxis is less clear in mild preeclampsia; however, we suggest prophylaxis in these women (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We recommend use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      for seizure prophylaxis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Seizure prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We give a loading dose of 6 grams",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      intravenously over 15 to 20 minutes followed by 2 grams per hour as a continuous infusion. The maintenance dose (but not the loading dose) should be adjusted in women with renal insufficiency. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Magnesium regimen and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Magnesium toxicity is related to serum concentration: loss of deep tendon reflexes occurs at 8 to 10",
"      <span class=\"nowrap\">",
"       mEq/L,",
"      </span>",
"      respiratory paralysis at 10 to 15",
"      <span class=\"nowrap\">",
"       mEq/L,",
"      </span>",
"      and cardiac arrest at 20 to 25",
"      <span class=\"nowrap\">",
"       mEq/L.",
"      </span>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"       Calcium gluconate",
"      </a>",
"      (1 gram intravenously over 5 to 10 minutes) should be administered to counteract life-threatening symptoms of magnesium toxicity. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Complications and side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is an increased risk of preeclampsia recurrence in subsequent pregnancies and possible long-term risks of cardiovascular disease. (See",
"      <a class=\"local\" href=\"#H21332929\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/1\">",
"      ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/2\">",
"      Heard AR, Dekker GA, Chan A, et al. Hypertension during pregnancy in South Australia, part 1: pregnancy outcomes. Aust N Z J Obstet Gynaecol 2004; 44:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/3\">",
"      Hauth JC, Ewell MG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000; 95:24.",
"     </a>",
"    </li>",
"    <li>",
"     Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. NICE Clinical Guideline. file://www.guideline.gov/content.aspx?id=24122 (Accessed on January 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/5\">",
"      Schiff E, Friedman SA, Kao L, Sibai BM. The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol 1996; 175:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/6\">",
"      Hall DR, Odendaal HJ, Steyn DW, Grov&eacute; D. Urinary protein excretion and expectant management of early onset, severe pre-eclampsia. Int J Gynaecol Obstet 2002; 77:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/7\">",
"      von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011; 377:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/8\">",
"      Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010; 115:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/9\">",
"      Coppage KH, Polzin WJ. Severe preeclampsia and delivery outcomes: is immediate cesarean delivery beneficial? Am J Obstet Gynecol 2002; 186:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/10\">",
"      Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999; 180:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/11\">",
"      Nassar AH, Adra AM, Chakhtoura N, et al. Severe preeclampsia remote from term: labor induction or elective cesarean delivery? Am J Obstet Gynecol 1998; 179:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/12\">",
"      Sibai BM. Diagnosis and management of gestational hypertension and preeclampsia. Obstet Gynecol 2003; 102:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/13\">",
"      Alexander JM, Bloom SL, McIntire DD, Leveno KJ. Severe preeclampsia and the very low birth weight infant: is induction of labor harmful? Obstet Gynecol 1999; 93:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/14\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/15\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/16\">",
"      Koopmans CM, Bijlenga D, Groen H, et al. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet 2009; 374:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/17\">",
"      Vijgen SM, Koopmans CM, Opmeer BC, et al. An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre-eclampsia at term (HYPITAT trial). BJOG 2010; 117:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/18\">",
"      Tajik P, van der Tuuk K, Koopmans CM, et al. Should cervical favourability play a role in the decision for labour induction in gestational hypertension or mild pre-eclampsia at term? An exploratory analysis of the HYPITAT trial. BJOG 2012; 119:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/19\">",
"      Magee LA, Helewa M, Moutquin JM, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/20\">",
"      Barton JR, Istwan NB, Rhea D, et al. Cost-savings analysis of an outpatient management program for women with pregnancy-related hypertensive conditions. Dis Manag 2006; 9:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/21\">",
"      Barton JR, Stanziano GJ, Sibai BM. Monitored outpatient management of mild gestational hypertension remote from term. Am J Obstet Gynecol 1994; 170:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/22\">",
"      Turnbull DA, Wilkinson C, Gerard K, et al. Clinical, psychosocial, and economic effects of antenatal day care for three medical complications of pregnancy: a randomised controlled trial of 395 women. Lancet 2004; 363:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/23\">",
"      Waugh J, Bosio P, Shennan A, Halligan A. Inpatient monitoring on an outpatient basis: managing hypertensive pregnancies in the community using automated technologies. J Soc Gynecol Investig 2001; 8:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/24\">",
"      Helewa M, Heaman M, Robinson MA, Thompson L. Community-based home-care program for the management of pre-eclampsia: an alternative. CMAJ 1993; 149:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/25\">",
"      Pfeifer TA. Expression of heterologous proteins in stable insect cell culture. Curr Opin Biotechnol 1998; 9:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/26\">",
"      Goldenberg RL, Cliver SP, Bronstein J, et al. Bed rest in pregnancy. Obstet Gynecol 1994; 84:131.",
"     </a>",
"    </li>",
"    <li>",
"     Working group report on high blood pressure in pregnancy. National Institutes of Health, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/28\">",
"      Unger C, Biedermann K, Szloboda J, et al. [Sodium concentration and pre-eclampsia: is salt restriction of value?]. Z Geburtshilfe Neonatol 1998; 202:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/29\">",
"      Nabeshima K. [Effect of salt restriction on preeclampsia]. Nihon Jinzo Gakkai Shi 1994; 36:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/30\">",
"      Mattar F, Sibai BM. Prevention of preeclampsia. Semin Perinatol 1999; 23:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/31\">",
"      Ganzevoort W, Rep A, Bonsel GJ, et al. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. BJOG 2005; 112:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/32\">",
"      Chang EY, Menard MK, Vermillion ST, et al. The association between hyaline membrane disease and preeclampsia. Am J Obstet Gynecol 2004; 191:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/33\">",
"      Langenveld J, Ravelli AC, van Kaam AH, et al. Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry. Am J Obstet Gynecol 2011; 205:540.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/34\">",
"      Wallace DH, Leveno KJ, Cunningham FG, et al. Randomized comparison of general and regional anesthesia for cesarean delivery in pregnancies complicated by severe preeclampsia. Obstet Gynecol 1995; 86:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/35\">",
"      Li YH, Novikova N. Pulmonary artery flow catheters for directing management in pre-eclampsia. Cochrane Database Syst Rev 2012; :CD008882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/36\">",
"      Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/37\">",
"      Livingston JC, Livingston LW, Ramsey R, et al. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2003; 101:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/38\">",
"      Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol 1998; 92:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/39\">",
"      Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998; 105:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/40\">",
"      Roberts JM, Villar J, Arulkumaran S. Preventing and treating eclamptic seizures. BMJ 2002; 325:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/41\">",
"      Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995; 333:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/42\">",
"      Belfort MA, Anthony J, Saade GR, et al. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 2003; 348:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/43\">",
"      Alexander JM, McIntire DD, Leveno KJ, Cunningham FG. Selective magnesium sulfate prophylaxis for the prevention of eclampsia in women with gestational hypertension. Obstet Gynecol 2006; 108:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/44\">",
"      Duley L, Matar HE, Almerie MQ, Hall DR. Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia. Cochrane Database Syst Rev 2010; :CD007388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/45\">",
"      Hall DR, Odendaal HJ, Smith M. Is the prophylactic administration of magnesium sulphate in women with pre-eclampsia indicated prior to labour? BJOG 2000; 107:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/46\">",
"      Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol 2004; 190:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/47\">",
"      Sibai BM, Lipshitz J, Anderson GD, Dilts PV Jr. Reassessment of intravenous MgSO4 therapy in preeclampsia-eclampsia. Obstet Gynecol 1981; 57:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/48\">",
"      Taber EB, Tan L, Chao CR, et al. Pharmacokinetics of ionized versus total magnesium in subjects with preterm labor and preeclampsia. Am J Obstet Gynecol 2002; 186:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/49\">",
"      Ehrenberg HM, Mercer BM. Abbreviated postpartum magnesium sulfate therapy for women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2006; 108:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/50\">",
"      Ascarelli MH, Johnson V, May WL, et al. Individually determined postpartum magnesium sulfate therapy with clinical parameters to safely and cost-effectively shorten treatment for pre-eclampsia. Am J Obstet Gynecol 1998; 179:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/51\">",
"      Isler CM, Barrilleaux PS, Rinehart BK, et al. Repeat postpartum magnesium sulfate administration for seizure prophylaxis: is there a patient profile predictive of need for additional therapy? J Matern Fetal Neonatal Med 2002; 11:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/52\">",
"      Isler CM, Barrilleaux PS, Rinehart BK, et al. Postpartum seizure prophylaxis: using maternal clinical parameters to guide therapy. Obstet Gynecol 2003; 101:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/53\">",
"      Fontenot MT, Lewis DF, Frederick JB, et al. A prospective randomized trial of magnesium sulfate in severe preeclampsia: use of diuresis as a clinical parameter to determine the duration of postpartum therapy. Am J Obstet Gynecol 2005; 192:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/54\">",
"      Miles JF Jr, Martin JN Jr, Blake PG, et al. Postpartum eclampsia: a recurring perinatal dilemma. Obstet Gynecol 1990; 76:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/55\">",
"      Smith JM, Lowe RF, Fullerton J, et al. An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management. BMC Pregnancy Childbirth 2013; 13:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/56\">",
"      Magee LA, Miremadi S, Li J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005; 193:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/57\">",
"      Szal SE, Croughan-Minihane MS, Kilpatrick SJ. Effect of magnesium prophylaxis and preeclampsia on the duration of labor. Am J Obstet Gynecol 1999; 180:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/58\">",
"      Duffy CR, Odibo AO, Roehl KA, et al. Effect of magnesium sulfate on fetal heart rate patterns in the second stage of labor. Obstet Gynecol 2012; 119:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/59\">",
"      Gray SE, Rodis JF, Lettieri L, et al. Effect of intravenous magnesium sulfate on the biophysical profile of the healthy preterm fetus. Am J Obstet Gynecol 1994; 170:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/60\">",
"      Cholst IN, Steinberg SF, Tropper PJ, et al. The influence of hypermagnesemia on serum calcium and parathyroid hormone levels in human subjects. N Engl J Med 1984; 310:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/61\">",
"      Hallak M. Effect of parenteral magnesium sulfate administration on excitatory amino acid receptors in the rat brain. Magnes Res 1998; 11:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/62\">",
"      Cotton DB, Hallak M, Janusz C, et al. Central anticonvulsant effects of magnesium sulfate on N-methyl-D-aspartate-induced seizures. Am J Obstet Gynecol 1993; 168:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/63\">",
"      Belfort MA, Clark SL, Sibai B. Cerebral hemodynamics in preeclampsia: cerebral perfusion and the rationale for an alternative to magnesium sulfate. Obstet Gynecol Surv 2006; 61:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/64\">",
"      Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 2009; 114:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/65\">",
"      Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008; 112:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/66\">",
"      Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/67\">",
"      van Rijn BB, Hoeks LB, Bots ML, et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/68\">",
"      Bramham K, Briley AL, Seed P, et al. Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study. Am J Obstet Gynecol 2011; 204:512.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/69\">",
"      Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/70\">",
"      Campbell DM, MacGillivray I, Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol 1985; 92:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/71\">",
"      Xiong X, Fraser WD, Demianczuk NN. History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Am J Obstet Gynecol 2002; 187:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/72\">",
"      Sibai BM, Sarinoglu C, Mercer BM. Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis. Am J Obstet Gynecol 1992; 166:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/73\">",
"      Mostello D, Kallogjeri D, Tungsiripat R, Leet T. Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol 2008; 199:55.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/74\">",
"      McDonald SD, Best C, Lam K. The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort. BJOG 2009; 116:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/75\">",
"      Trogstad L, Skrondal A, Stoltenberg C, et al. Recurrence risk of preeclampsia in twin and singleton pregnancies. Am J Med Genet A 2004; 126A:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/76\">",
"      Chang JJ, Muglia LJ, Macones GA. Association of early-onset pre-eclampsia in first pregnancy with normotensive second pregnancy outcomes: a population-based study. BJOG 2010; 117:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/77\">",
"      Wikstr&ouml;m AK, Stephansson O, Cnattingius S. Previous preeclampsia and risks of adverse outcomes in subsequent nonpreeclamptic pregnancies. Am J Obstet Gynecol 2011; 204:148.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/78\">",
"      Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. BMJ 2007; 335:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/79\">",
"      McDonald SD, Malinowski A, Zhou Q, et al. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008; 156:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/80\">",
"      Fraser A, Nelson SM, Macdonald-Wallis C, et al. Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children. Circulation 2012; 125:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/81\">",
"      Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001; 323:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/82\">",
"      Chesley SC, Annitto JE, Cosgrove RA. The remote prognosis of eclamptic women. Sixth periodic report. Am J Obstet Gynecol 1976; 124:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/83\">",
"      Chambers JC, Fusi L, Malik IS, et al. Association of maternal endothelial dysfunction with preeclampsia. JAMA 2001; 285:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/84\">",
"      Agatisa PK, Ness RB, Roberts JM, et al. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart Circ Physiol 2004; 286:H1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/85\">",
"      Lampinen KH, R&ouml;nnback M, Kaaja RJ, Groop PH. Impaired vascular dilatation in women with a history of pre-eclampsia. J Hypertens 2006; 24:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/86\">",
"      Yinon Y, Kingdom JC, Odutayo A, et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. Circulation 2010; 122:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/87\">",
"      Hermes W, Ket JC, van Pampus MG, et al. Biochemical cardiovascular risk factors after hypertensive pregnancy disorders: a systematic review and meta-analysis. Obstet Gynecol Surv 2012; 67:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/88\">",
"      Magnussen EB, Vatten LJ, Lund-Nilsen TI, et al. Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study. BMJ 2007; 335:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/89\">",
"      Magnussen EB, Vatten LJ, Smith GD, Romundstad PR. Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors. Obstet Gynecol 2009; 114:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/90\">",
"      Romundstad PR, Magnussen EB, Smith GD, Vatten LJ. Hypertension in pregnancy and later cardiovascular risk: common antecedents? Circulation 2010; 122:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/91\">",
"      Kaaja RJ, P&ouml;yh&ouml;nen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/92\">",
"      Kaaja RJ, Greer IA. Manifestations of chronic disease during pregnancy. JAMA 2005; 294:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/93\">",
"      Stekkinger E, Zandstra M, Peeters LL, Spaanderman ME. Early-onset preeclampsia and the prevalence of postpartum metabolic syndrome. Obstet Gynecol 2009; 114:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/94\">",
"      Zandstra M, Stekkinger E, van der Vlugt MJ, et al. Cardiac diastolic dysfunction and metabolic syndrome in young women after placental syndrome. Obstet Gynecol 2010; 115:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/95\">",
"      Lykke JA, Langhoff-Roos J, Sibai BM, et al. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension 2009; 53:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/96\">",
"      Vikse BE, Irgens LM, Leivestad T, et al. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/97\">",
"      Wang IK, Muo CH, Chang YC, et al. Association between hypertensive disorders during pregnancy and end-stage renal disease: a population-based study. CMAJ 2013; 185:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/98\">",
"      Levine RJ, Vatten LJ, Horowitz GL, et al. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ 2009; 339:b4336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/99\">",
"      Wilson KL, Casey BM, McIntire DD, et al. Subclinical thyroid disease and the incidence of hypertension in pregnancy. Obstet Gynecol 2012; 119:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/100\">",
"      Arnadottir GA, Geirsson RT, Arngrimsson R, et al. Cardiovascular death in women who had hypertension in pregnancy: a case-control study. BJOG 2005; 112:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/101\">",
"      Mogren I, Stenlund H, H&ouml;gberg U. Long-term impact of reproductive factors on the risk of cervical, endometrial, ovarian and breast cancer. Acta Oncol 2001; 40:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/102\">",
"      Cohn BA, Cirillo PM, Christianson RE, et al. Placental characteristics and reduced risk of maternal breast cancer. J Natl Cancer Inst 2001; 93:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/103\">",
"      Vatten LJ, Romundstad PR, Trichopoulos D, Skjaerven R. Pre-eclampsia in pregnancy and subsequent risk for breast cancer. Br J Cancer 2002; 87:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/104\">",
"      Polednak AP, Janerich DT. Characteristics of first pregnancy in relation to early breast cancer. A case-control study. J Reprod Med 1983; 28:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/105\">",
"      Aagaard-Tillery KM, Stoddard GJ, Holmgren C, et al. Preeclampsia and subsequent risk of cancer in Utah. Am J Obstet Gynecol 2006; 195:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/106\">",
"      Paltiel O, Friedlander Y, Tiram E, et al. Cancer after pre-eclampsia: follow up of the Jerusalem perinatal study cohort. BMJ 2004; 328:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/23/21882/abstract/107\">",
"      Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Preeclampsia and subsequent risk of cancer: update from the Jerusalem Perinatal Study. Am J Obstet Gynecol 2009; 200:63.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6825 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C9EBEEE8B0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21882=[""].join("\n");
var outline_f21_23_21882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31268781\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31268819\">",
"      APPROACH BASED ON DISEASE SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31268927\">",
"      Severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mild preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H703219\">",
"      EXPECTANT ANTEPARTUM MANAGEMENT OF MILD PREECLAMPSIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Inpatient versus outpatient care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Assessment of fetal well-being",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Assessment of fetal growth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antenatal corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H703332\">",
"      INTRAPARTUM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intrapartum monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H961072\">",
"      Fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H961079\">",
"      Management of hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H704577\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Invasive hemodynamic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Seizure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Magnesium sulfate versus other anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Magnesium regimen and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H704368\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H704472\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Complications and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8632592\">",
"      Mechanism of anticonvulsant action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      POSTPARTUM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H960515\">",
"      GUIDELINES FROM SELECTED ORGANIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21332929\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21332951\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H707032\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H707006\">",
"      Risk of related obstetrical complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21332965\">",
"      Long-term maternal risks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21332973\">",
"      - Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21332980\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21332987\">",
"      - End-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H707175\">",
"      - Subclinical hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21332994\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6825|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 1A\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22739\" title=\"picture 1B\">",
"      Helmet cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6825|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/60/43979\" title=\"table 2\">",
"      Criteria for severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/37/4699\" title=\"table 3\">",
"      Late cardiovasc death preeclamp",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34248?source=related_link\">",
"      Airway management of pregnant women at delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/58/13220?source=related_link\">",
"      Causes and treatment of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32808?source=related_link\">",
"      Expectant management of severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=related_link\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14520?source=related_link\">",
"      Incidence and mortality of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13814?source=related_link\">",
"      Long-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36567?source=related_link\">",
"      Management of myasthenia gravis in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29410?source=related_link\">",
"      Patient information: HELLP syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=related_link\">",
"      Patient information: High blood pressure and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/53/28498?source=related_link\">",
"      Patient information: Preeclampsia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=related_link\">",
"      Symptoms of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_23_21883="Heat or cold therapy contraindications";
var content_f21_23_21883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F86678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F86678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications for heat and cold therapeutic modalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Heat",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute injury/trauma/hemorrhage",
"       </td>",
"       <td>",
"        Ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insensate skin",
"       </td>",
"       <td>",
"        Insensate skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ischemia",
"       </td>",
"       <td>",
"        Inability to communicate/respond to pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Edema",
"       </td>",
"       <td>",
"        Impaired thermal regulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to communicate/respond to pain",
"       </td>",
"       <td>",
"        Raynaud's phenomenon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired thermal regulation",
"       </td>",
"       <td rowspan=\"3\">",
"        Pronounced cold pressor response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac disorders (eg, decompensated heart failure)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: DeLisa's Physcial Medicine and Rehabilitation: Principles and Practice, 5th edition, Frontera WR (Ed), Lippincott Williams &amp; Wilkins, 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21883=[""].join("\n");
var outline_f21_23_21883=null;
var title_f21_23_21884="Pediatric HIV classification - clinical";
var content_f21_23_21884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric HIV classification system - clinical categories",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category N: Not symptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No signs or symptoms considered to be the result of HIV infection or only one of the conditions listed in Category A.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category A: Mildly symptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Two or more of the following without any of the conditions listed in Categories B and C: Lymphadenopathy (&ge;0.5 cm at more than two sites; bilateral-one site); hepatomegaly; splenomegaly; dermatitis; parotitis; recurrent or persistent upper respiratory infection, sinusitis, or otitis media.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category B: Moderately symptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic conditions attributed to HIV infection other than those listed for Category A or C including but not limited to: Anemia (&lt;8 gm/dL), neutropenia (&lt;1,000/microL), or thrombocytopenia (&lt;100,000/microL) persisting &ge;30 days; bacterial meningitis, pneumonia, or sepsis (single episode); oropharyngeal candidiasis persisting for &gt;2 months; cardiomyopathy; cytomegalovirus (CMV) infection with onset before age 1 month; recurrent or chronic diarrhea; hepatitis; recurrent herpes simplex virus (HSV) stomatitis (&gt;2 episodes within 1 year); HSV bronchitis, pneumonitis, or esophagitis with onset before age 1 month; herpes zoster involving at least two distinct episodes or more than one dermatone; leiomyosarcoma; lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid hyperplasia (PLH) complex; nephropathy; nocardiosis; fever lasting &gt;1 month; toxoplasmosis with onset before age 1 month; disseminated varicella.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Category C: Severely symptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any condition listed in the 1987 surveillance case definition for AIDS, with the exception of LIP (which is a Category B condition): Esophageal or pulmonary candidiasis; multiple or recurrent serious bacterial infections; CMV infection with onset after age 1 month at a site other than liver, spleen, or lymph nodes; Pneumocystis carinii pneumonia (PCP); wasting syndrome; HIV encephalopathy; HSV bronchitis, pneumonitis, or esophagitis after age 1 month or ucler persisting for &gt;1 month; Kaposi's sarcoma; Burkitt, immunoblastic, or large cell lymphoma; primary brain lymphoma; toxoplasmosis of the brain with onset after age 1 month; disseminated atypical mycobacterial infection; disseminated coccidioidomycosis; disseminated histoplasmosis; cryptosporidioisis or isosporiasis with diarrhea persisting &ge;1 month; extrapulmonary cryptococcosis; extrapulmonary TB; recurrent Salmonella bacteremia; progressive multifocal leukoencephalopathy.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Centers for Disease Control and Prevention. MMWR Recomm Rep 1994; 43(RR-12):1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21884=[""].join("\n");
var outline_f21_23_21884=null;
var title_f21_23_21885="Normal ausculatory findings of prosthetic valves";
var content_f21_23_21885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61951%7ECARD%2F70856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61951%7ECARD%2F70856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal auscultatory findings of prosthetic valves according to type and location",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Valve prosthesis",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Auscultatory Findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Mitral",
"       </td>",
"       <td class=\"subtitle2\">",
"        Aortic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Ball valves- eg, Starr-Edwards&nbsp;&nbsp;",
"       </td>",
"       <td colspan=\"1\">",
"        A2-MO interval 0.07-0.11 second",
"       </td>",
"       <td>",
"        S1-AO interval 0.07 second",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MO louder than MC",
"       </td>",
"       <td>",
"        AO louder than AC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft systolic murmur",
"       </td>",
"       <td>",
"        Soft, harsh systolic ejection murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No diastolic murmur",
"       </td>",
"       <td>",
"        \"Seating puff\" - diastolic rumble",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        Disc valves- eg, Bjork-Shiley&nbsp;&nbsp;",
"       </td>",
"       <td colspan=\"1\">",
"        A2-MO interval 0.05-0.09 second",
"       </td>",
"       <td>",
"        S1-AO interval 0.04 second",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MO is soft or may not be audible",
"       </td>",
"       <td>",
"        AC louder than AO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft systolic murmur",
"       </td>",
"       <td>",
"        Soft systolic ejection murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft and short diastolic rumble",
"       </td>",
"       <td>",
"        \"Seating puff\" - diastolic rumble",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Tissue valves- eg, Hancock&nbsp;&nbsp;&nbsp;",
"       </td>",
"       <td colspan=\"1\">",
"        A2-MO interval 0.1 second",
"       </td>",
"       <td>",
"        S1-AO interval 0.03-0.08 second",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MC louder than MO",
"       </td>",
"       <td>",
"        AC louder than AO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MO is audible in approximately 50 percent",
"       </td>",
"       <td>",
"        AO may be absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft apical systolic murmur",
"       </td>",
"       <td>",
"        Soft systolic ejection murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soft diastolic ramble",
"       </td>",
"       <td>",
"        No diastolic rumble",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Bi-leaflet valves- eg, St. Jude",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Loud AO and AC&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Soft systolic ejection murmur",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A2: aortic valve closure sound; MO: mitral prosthesis opening sound; MC: mitral prosthesis closing sound; S1: first heart sound; AO: aortic prosthesis opening sound; AC: aortic prosthesis closing sound.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Smith ND, Ralzada V, Abrams J: Auscultation of the normally functioning prosthetic valve. Ann Intern Med 95:594, 1981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Abnormal auscultatory findings in patients with prosthetic heart valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aortic valve",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mitral valve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"        Caged-ball (Starr-Edwards)",
"       </td>",
"       <td>",
"        Aortic diastolic murmur",
"       </td>",
"       <td>",
"        Low frequency apical diastolic murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased intensity of opening or closing click",
"       </td>",
"       <td>",
"        High frequency holosystolic murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"        Single-tilting-disk (Bjork-Shiley or Medtronic-Hall)",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Decreased intensity of closing click",
"       </td>",
"       <td>",
"        High frequency holosystolic murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased intensity of closing click",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"1\" rowspan=\"2\">",
"        Bileaflet-tilting-disk (St. Jude Medical)",
"       </td>",
"       <td>",
"        Aortic diastolic murmur",
"       </td>",
"       <td>",
"        High frequency holosystolic murmur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased intensity of closing click",
"       </td>",
"       <td>",
"        Decreased intensity of closing click",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Heterograft bioprosthesis (Hancock or Carpentier-Edwards)",
"       </td>",
"       <td>",
"        Aortic diastolic murmur",
"       </td>",
"       <td>",
"        High frequency holosystolic murmur",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Vongpatanasin, W, Hillis, LD, Lange, RA, N Engl J Med 1996; 335:407.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21885=[""].join("\n");
var outline_f21_23_21885=null;
var title_f21_23_21886="Weight loss with phentermine";
var content_f21_23_21886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Weight loss with phentermine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 259px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both continuous and intermittent therapy with phentermine result in more weight loss than placebo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Munro, JF, MacCuish, AC, Wilson, EM, Duncan, LJ, BMJ 1968; 1:352.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21886=[""].join("\n");
var outline_f21_23_21886=null;
var title_f21_23_21887="Unicornuate uter and xtra horn";
var content_f21_23_21887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unicornuate uterus with uterine horn (not containing an endometrial cavity) not fused to unicornuate uterus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_23_21887=[""].join("\n");
var outline_f21_23_21887=null;
